%PDF-1.3
%‚„œ”
1 0 obj
<<
/Length 10494
>>
stream
/GS0 gs
q
0 0.701 595 793 re
W n
1 g
0 793.701 0 0 re
f
Q
/GS0 gs
/GS2 gs
q
0 0 0 0 k
42.52 51.024 510.236 657.638 re
f
527.244 18.126 25.512 16.673 re
f
BT
/F0 1 Tf
8 0 0 8 544.7559 19.8606 Tm
0 Tr
0 0 0 1 k
(80)Tj
ET
0 0 0 0 k
42.52 51.024 510.236 439.37 re
f
BT
/F1 1 Tf
8.5 0 0 8.5 42.5197 483.9609 Tm
0 0 0 1 k
-0.0002 Tc
(Resumen)Tj
ET
BT
/F2 1 Tf
8.5 0 0 8.5 53.8583 464.9609 Tm
(Objetivo:)Tj
ET
BT
/F3 1 Tf
8.5 0 0 8.5 95.4087 464.9609 Tm
-0.0001 Tc
0.0699 Tw
(Describir el caso de una paciente diagnosticada de)Tj
-6.22224 -1.11765 TD
0 Tc
0.186 Tw
(glomerulonefritis membranosa y neutropenia no central autoin-)Tj
-0.0001 Tc
0.0943 Tw
(mune en tratamiento con ciclosporina, que desarroll\227 un cuadro)'
0 -1.11764 TD
0 Tw
(de cefalea intensa e incapacitante. )Tj
ET
BT
/F2 1 Tf
8.5 0 0 8.5 53.8583 426.9609 Tm
-0.0002 Tc
0.0044 Tw
(Descripci\227n del caso: )Tj
ET
BT
/F3 1 Tf
8.5 0 0 8.5 146.5926 426.9609 Tm
-0.0001 Tc
0.0039 Tw
(Paciente de 66 a\226os de edad, sin his)Tj
15.80279 0 TD
0 Tc
(-)Tj
-28.04666 -1.11765 TD
0.021 Tw
(toria de cefaleas ni de reacciones adversas a medicamentos, diag-)Tj
0 -1.11764 TD
-0.027 Tw
(nosticada de glomerulonefritis membranosa y neutropenia no cen-)Tj
0 -1.11765 TD
-0.0001 Tc
0.0934 Tw
(tral autoinmune. Se inici\227 ciclosporina A neoral a dosis de unos)Tj
0.0814 Tw
(2,5 mg/kg/24 h (100 mg/12 h), con niveles de ciclosporina A,)'
0 -1.11764 TD
-0.0161 Tw
(en sangre total, dentro del \207mbito terap\216utico. La paciente refiri\227,)Tj
0 -1.11765 TD
0 Tc
0.075 Tw
(5 d\222as despu\216s, un cuadro de cefalea holocraneal intensa e inca-)Tj
-0.0001 Tc
0.0992 Tw
(pacitante. La tomograf\222a computerizada craneal fue normal y se)'
0 -1.11764 TD
0.0815 Tw
(descartaron otras causas de cefalea, que s\227lo desapareci\227 con la)Tj
0 -1.11765 TD
0 Tw
(supresi\227n de la ciclosporina. )Tj
ET
BT
/F2 1 Tf
8.5 0 0 8.5 53.8583 331.9609 Tm
-0.0002 Tc
(Comentario:)Tj
ET
BT
/F3 1 Tf
8.5 0 0 8.5 109.8362 331.9609 Tm
0 Tc
0.147 Tw
(La cefalea intensa es un efecto adverso infre-)Tj
-7.91959 -1.11764 TD
-0.0001 Tc
0.0394 Tw
(cuente de la ciclosporina que es importante conocer porque pue)Tj
28.04666 0 TD
0 Tc
(-)Tj
-28.04666 -1.11765 TD
-0.0001 Tc
-0.0141 Tw
(de comprometer la adherencia al tratamiento y puede hacer nece)Tj
28.04666 0 TD
0 Tc
(-)Tj
-28.04666 -1.11765 TD
-0.0001 Tc
0.6091 Tw
(saria la suspensi\227n del f\207rmaco. La imputabilidad de la)Tj
0.1481 Tw
(ciclosporina con este efecto neurot\227xico se analiz\227 a trav\216s del)'
0 -1.11764 TD
0.0037 Tw
(m\216todo de estimaci\227n de la probabilidad de reacciones adversas a)Tj
0.059 Tw
(medicamentos de Naranjo, obteni\216ndose una relaci\227n de causali)'
28.04665 0.00001 TD
0 Tc
(-)Tj
-28.04665 -1.11766 TD
-0.0002 Tc
0 Tw
(dad de )Tj
ET
BT
/F4 1 Tf
8.5 0 0 8.5 69.3706 265.4609 Tm
(probable)Tj
ET
BT
/F3 1 Tf
8.5 0 0 8.5 102.8498 265.4609 Tm
0 Tc
(.)Tj
ET
BT
/F1 1 Tf
8.5 0 0 8.5 42.5197 246.4609 Tm
-0.0001 Tc
(Palabras clave:)Tj
ET
BT
/F3 1 Tf
8.5 0 0 8.5 112.8813 246.4609 Tm
(Ciclosporina. Cefalea. Reacci\227n adversa.)Tj
ET
BT
/F1 1 Tf
8.5 0 0 8.5 42.5197 208.4609 Tm
(Summary)Tj
ET
BT
/F2 1 Tf
8.5 0 0 8.5 53.8583 189.4609 Tm
-0.0002 Tc
(Objective:)Tj
ET
BT
/F3 1 Tf
8.5 0 0 8.5 100.4033 189.4609 Tm
-0.0001 Tc
0.1978 Tw
(To report the case of a patient diagnosed with)Tj
-6.80983 -1.11765 TD
0.4185 Tw
(membranous glomerulonephritis and autoimmune non-central)Tj
0 -1.11764 TD
0.3089 Tw
(neutropenia under treatment with cyclosporin who developed)Tj
0 Tw
(severe, disabling headache. )'
ET
BT
/F2 1 Tf
8.5 0 0 8.5 323.1496 483.9609 Tm
-0.0205 Tc
0.1676 Tw
(Case report:)Tj
ET
BT
/F3 1 Tf
8.5 0 0 8.5 378.493 483.9609 Tm
-0.0181 Tc
0.1479 Tw
(A 66-year-old female patient with no history of)Tj
-7.84494 -1.11765 TD
-0.018 Tc
0.169 Tw
(headache or adverse drug reactions was diagnosed with membra-)Tj
0 -1.11764 TD
-0.0181 Tc
0.1141 Tw
(nous glomerulonephritis and autoimmune non-central neutropenia.)Tj
0 -1.11765 TD
(Neoral)Tj
4.25 0 0 4.25 335.3702 458.6484 Tm
0 Tc
<A8>Tj
8.5 0 0 8.5 341.8586 455.4609 Tm
-0.0181 Tc
0.0906 Tw
((cyclosporin A) was initiated at a dose of 2.5 mg/kg/24 h)Tj
-3.53501 -1.11765 TD
-0.018 Tc
-0.01 Tw
((100 mg/12 h), with whole blood cyclosporin levels within the thera-)Tj
0 -1.11764 TD
-0.0181 Tc
0.1158 Tw
(peutic range. After 5 days the patient reported holocranial severe,)Tj
0 -1.11765 TD
0.0145 Tw
(disabling headache. A cranial CT scan was normal and other heada)Tj
28.04666 0 TD
0 Tc
(-)Tj
-28.04666 -1.11765 TD
-0.0181 Tc
0.143 Tw
(che causes were also ruled out; her headache subsided only upon)Tj
0 -1.11764 TD
0 Tw
(cyclosporin discontinuation. )Tj
ET
BT
/F2 1 Tf
8.5 0 0 8.5 323.1496 398.4609 Tm
-0.0002 Tc
(Comment:)Tj
ET
BT
/F3 1 Tf
8.5 0 0 8.5 369.9112 398.4609 Tm
-0.0001 Tc
0.0827 Tw
(Severe headache is an uncommon adverse effect)Tj
-6.83532 -1.11765 TD
0 Tc
-0.023 Tw
(of cyclosporin whose recognition is relevant, since it may compro-)Tj
0 -1.11764 TD
-0.0001 Tc
-0.0245 Tw
(mise therapy compliance and require the drug  to be discontinued.)Tj
0 -1.11765 TD
0.2818 Tw
(The attribution of cyclosporin with this neurotoxic effect was)Tj
T*
0 Tc
0.013 Tw
(analyzed using Naranjo\325s probability estimation method for adver-)Tj
0 -1.11764 TD
-0.0001 Tc
0.2142 Tw
(se drug reactions, which resulted in causality being considered)Tj
ET
BT
/F4 1 Tf
8.5 0 0 8.5 311.811 341.4609 Tm
-0.0002 Tc
(probable.)Tj
ET
BT
/F1 1 Tf
8.5 0 0 8.5 311.811 322.4609 Tm
0 Tw
(Key words:)Tj
ET
BT
/F3 1 Tf
8.5 0 0 8.5 362.9667 322.4609 Tm
-0.0001 Tc
(Cyclosporin. )Tj
5.73852 0 TD
0 Tc
(H)Tj
0.79981 0 TD
-0.0001 Tc
(eadache. )Tj
4.13916 0 TD
0 Tc
(A)Tj
0.71997 0 TD
-0.0001 Tc
(dverse reaction.)Tj
ET
0 J 0 j 0.4 i 10 M []0 d 0.667 w 
0 0 0 1 K
311.811 310.628 m
552.756 310.628 l
S
311.811 309.294 m
552.756 309.294 l
S
BT
/F2 1 Tf
10.5 0 0 10.5 311.811 241.9609 Tm
-0.0002 Tc
(INTRODUCCI\356N)Tj
ET
BT
/F0 1 Tf
10.5 0 0 10.5 323.1496 218.9609 Tm
0 Tc
0.118 Tw
[(La ciclosporina es un polip\216ptido de 1)37(1 amino\207cidos)]TJ
-1.07986 -1.09523 TD
-0.0001 Tc
0.1411 Tw
(obtenido a partir del hongo )Tj
ET
BT
/F5 1 Tf
10.5 0 0 10.5 435.5611 207.4609 Tm
0 Tc
(T)Tj
0.46411 0.00001 TD
-0.0001 Tc
(olypocladium inflatum. )Tj
ET
BT
/F0 1 Tf
10.5 0 0 10.5 543.4249 207.4609 Tm
-0.0003 Tc
(El)Tj
-22.05847 -1.09524 TD
0 Tc
0.106 Tw
(mecanismo de acci\227n consiste en la formaci\227n de com-)Tj
T*
0.086 Tw
[(plejos con la ciclofilina intracelular)40(, que se unen e inhi-)]TJ
0 -1.09523 TD
-0.0001 Tc
0.0325 Tw
(ben la calcineurina, lo que evita la activaci\227n de factores)Tj
0 -1.09524 TD
0.1011 Tw
(nucleares involucrados en la transcripci\227n de genes que)Tj
0 -1.09523 TD
0.0227 Tw
(codifican varias citocinas incluyendo la IL-2 y el interfe)Tj
22.61439 0.00001 TD
0 Tc
(-)Tj
-22.61439 -1.09525 TD
-0.0001 Tc
0.0139 Tw
(r\227n-gamma. El resultado final es la falta de activaci\227n de)Tj
0 -1.09524 TD
0.1154 Tw
(las c\216lulas T y de las respuestas inmunes mediadas por)Tj
0 -1.09523 TD
0.02 Tw
(estas c\216lulas. Ha sido utilizado con \216xito para prevenir el)Tj
0 -1.09524 TD
0.0422 Tw
(rechazo de \227r)Tj
5.45126 0.00001 TD
(ganos trasplantados, en el tratamiento de la)Tj
-5.45126 -1.09525 TD
0.0289 Tw
(diabetes mellitus tipo I, en las glomerulopat\222as, as\222 como)Tj
0 -1.09523 TD
0.0215 Tw
(en otras enfermedades autoinmunes como la uve\222tis idio)Tj
22.61437 0.00001 TD
0 Tc
(-)Tj
-22.61437 -1.09525 TD
0.09 Tw
[(p\207tica, artritis reumatoide, s\222ndrome de Sj\232gren\325)55(s, mias-)]TJ
0 -1.09524 TD
-0.0001 Tc
0.0199 Tw
(tenia )Tj
ET
BT
/F5 1 Tf
10.5 0 0 10.5 335.0505 57.9609 Tm
(gravis,)Tj
ET
BT
/F0 1 Tf
10.5 0 0 10.5 366.7546 57.9609 Tm
(psoriasis, etc. (1,2). En Espa\226a es un f\207rma)Tj
17.38164 0.00001 TD
0 Tc
(-)Tj
ET
BT
/F6 1 Tf
18 0 0 18 104.4278 668.0061 Tm
0.0008 Tc
0 Tw
(Cefalea asociada a ciclosporina en un paciente con)Tj
4.13904 -1.11111 TD
0.001 Tc
(glomerulonefritis membranosa)Tj
ET
BT
/F0 1 Tf
12 0 0 12 83.0133 615.0061 Tm
-0.0001 Tc
(J. BORR\347S BLASCO, R. ENR\352QUEZ)Tj
6 0 0 6 272.0045 619.0686 Tm
0 Tc
(1)Tj
12 0 0 12 275.0045 615.0061 Tm
[(, F)80(. AMOR\356S AMOR\356S)]TJ
6 0 0 6 398.3795 619.0686 Tm
(1)Tj
12 0 0 12 401.3795 615.0061 Tm
[(, A. NA)129(V)129(ARRO RUIZ, )]TJ
-19.5083 -1.08334 TD
[(V)129(. CONESA GARC\352A)]TJ
6 0 0 6 277.3805 606.0686 Tm
(2)Tj
12 0 0 12 280.3805 602.0061 Tm
-0.0001 Tc
(, M. GONZ\347LEZ DELGADO)Tj
ET
BT
/F5 1 Tf
10.5 0 0 10.5 56.8415 577.5061 Tm
0 Tc
(Servicio de Farmacia. )Tj
5.25 0 0 5.25 153.0564 581.0686 Tm
(1)Tj
10.5 0 0 10.5 155.6814 577.5061 Tm
[(Secci\227n de Nefr)37(olog\222a. )]TJ
5.25 0 0 5.25 253.8523 581.0686 Tm
(2)Tj
10.5 0 0 10.5 256.4773 577.5061 Tm
-0.0001 Tc
(Secci\227n de Hematolog\222a. Hospital General Universitario de Elche.)Tj
2.25403 -1.09524 TD
(Alicante)Tj
ET
BT
/F3 1 Tf
7 0 0 7 42.5197 758.048 Tm
-0.0002 Tc
(1130-6343/2004/28/6/454)Tj
0 -0.99999 TD
0 Tc
(F)Tj
5.25 0 0 5.25 46.4384 751.048 Tm
-0.0001 Tc
(ARMACIA)Tj
7 0 0 7 73.1041 751.048 Tm
0 Tc
(H)Tj
5.25 0 0 5.25 78.7027 751.048 Tm
-0.0001 Tc
(OSPITALARIA)Tj
7 0 0 7 42.5197 744.048 Tm
-0.0002 Tc
(Copyright \251 2004 )Tj
8.45751 0.00001 TD
0 Tc
(A)Tj
5.25 0 0 5.25 106.7621 744.048 Tm
-0.0001 Tc
(R\347N)Tj
7 0 0 7 120.0952 744.048 Tm
0 Tc
(E)Tj
5.25 0 0 5.25 124.2942 744.048 Tm
-0.0001 Tc
(DICIONES)Tj
7 0 0 7 149.0689 744.048 Tm
-0.0002 Tc
(, S. L)Tj
2.39893 0.00001 TD
0 Tc
(.)Tj
ET
0 0 0 0 k
42.52 57.701 240.945 86.932 re
f
0.5 w 
42.52 113.189 m
283.465 113.189 l
S
BT
/F5 1 Tf
8 0 0 8 42.5197 104.4354 Tm
0 0 0 1 k
-0.0001 Tc
(Recibido: )Tj
ET
BT
/F0 1 Tf
8 0 0 8 75.6154 104.4354 Tm
(15-01-2004)Tj
ET
BT
/F5 1 Tf
8 0 0 8 42.5197 95.4354 Tm
(Aceptado: )Tj
ET
BT
/F0 1 Tf
8 0 0 8 77.3927 95.4354 Tm
(03-03-2004)Tj
ET
BT
/F5 1 Tf
8 0 0 8 42.5197 77.4354 Tm
-0.0151 Tc
0.138 Tw
(Correspondencia: )Tj
ET
BT
/F0 1 Tf
8 0 0 8 101.7909 77.4354 Tm
-0.0001 Tc
(Joaqu\222n Borr\207s Blasco. Servicio de Farmacia. Hospital)Tj
-7.4089 -1.125 TD
0.0199 Tc
-0.0043 Tw
(General Universitario. Cam\222 de L\325Almazara, 11. 03203 Elche. Alicante.)Tj
T*
0 Tc
0 Tw
[(e)-20(-)-20(mail: jborrasb@sefh.es)]TJ
ET
BT
/F3 1 Tf
7 0 0 7 492.2203 760.3819 Tm
(F)Tj
5.25 0 0 5.25 496.139 760.3819 Tm
-0.0001 Tc
(ARM)Tj
7 0 0 7 510.1014 760.3819 Tm
0 Tc
(H)Tj
5.25 0 0 5.25 515.7 760.3819 Tm
-0.0002 Tc
(OSP)Tj
7 0 0 7 528.4012 760.3819 Tm
-0.0001 Tc
((Madrid))Tj
-11.99562 -1 TD
0 Tc
[(Vol. 28. N.\241)-300(6, pp. 454-457, 2004)]TJ
ET
0 0 0 0.2 k
437.387 738.942 115.369 11.13 re
f
BT
/F2 1 Tf
7 0 0 7 443.4214 742.54 Tm
0 0 0 1 k
-0.0001 Tc
(COMUNICACIONES CORTAS)Tj
ET
Q
endstream
endobj
2 0 obj
<<
/SA false
/OPM 1
/Type/ExtGState
/OP false
>>
endobj
3 0 obj
<<
/SA false
/OPM 1
/Type/ExtGState
/OP true
>>
endobj
4 0 obj
<<
/Length 10431
>>
stream
/GS0 gs
q
0 0.701 595 793 re
W n
1 g
0 793.701 0 0 re
f
Q
/GS0 gs
/GS2 gs
0 0 0 0 k
42.52 51.024 510.236 657.638 re
f
q
BT
/F0 1 Tf
10.5 0 0 10.5 42.5197 701.4813 Tm
0 Tr
0 0 0 1 k
0.08 Tw
[(co autorizado para el tratamiento del trasplante de \227r)18(ga-)]TJ
0 -1.09524 TD
-0.0001 Tc
0.1299 Tw
(nos y de m\216dula \227sea, y en enfermedades autoinmunes)Tj
0 -1.09523 TD
0 Tc
0.03 Tw
(tales como uve\222tis end\227gena, psoriasis, s\222ndrome nefr\227ti-)Tj
0 -1.09524 TD
-0.0001 Tc
0 Tw
(co, artritis reumatoide y dermatitis at\227pica severa.)Tj
1.07987 -1.09524 TD
0.0897 Tw
(Los efectos adversos m\207s frecuentes son deterioro de)Tj
-1.07987 -1.09523 TD
0.3677 Tw
(la funci\227n renal y hep\207tica, hipertricosis, temblores,)Tj
0 -1.09524 TD
0 Tc
0.064 Tw
(hipertensi\227n arterial, hipertrofia gingival, trastornos gas-)Tj
0 -1.09523 TD
-0.0001 Tc
0.0291 Tw
(trointestinales y sensaci\227n de quemaz\227n en manos y pies)Tj
0 -1.09524 TD
0.0376 Tw
((3,4). Presentamos el caso de una paciente diagnosticada)Tj
T*
0 Tc
0.085 Tw
(de glomerulonefritis membranosa y neutropenia no cen-)Tj
0 -1.09523 TD
0.041 Tw
[(tral autoinmune en tratamiento con este inmunosupresor)40(,)]TJ
0 -1.09524 TD
-0.019 Tw
(que desarroll\227 un cuadro de cefalea intensa e incapacitan-)Tj
0 -1.09523 TD
-0.0001 Tc
0 Tw
(te. )Tj
ET
BT
/F2 1 Tf
10.5 0 0 10.5 42.5197 528.9813 Tm
(DESCRIPCI\356N DEL CASO )Tj
ET
BT
/F0 1 Tf
10.5 0 0 10.5 53.8583 505.9813 Tm
0 Tc
0.002 Tw
(Paciente de 66 a\226os de edad, que fue remitida por ede-)Tj
-1.07987 -1.09523 TD
-0.0001 Tc
-0.0054 Tw
(mas, que hab\222an aparecido 6 semanas antes, en miembros)Tj
0 -1.09524 TD
0 Tc
0.109 Tw
(inferiores; no refer\222a otra sintomatolog\222a. Como antece-)Tj
0 -1.09523 TD
-0.01 Tw
(dentes personales destacaba asma bronquial; no ten\222a his-)Tj
0 -1.09524 TD
-0.0001 Tc
0.023 Tw
(toria de cefaleas ni de reacciones adversas a medicamen)Tj
22.61438 0 TD
0 Tc
(-)Tj
-22.61438 -1.09524 TD
-0.0001 Tc
(tos.)Tj
1.07987 -1.09524 TD
0.3863 Tw
(Exploraci\227n f\222sica: afebril, tensi\227n arterial 120/80)Tj
-1.07987 -1.09524 TD
0 Tc
0.014 Tw
(mmHg, edemas con f\227vea hasta rodillas; el resto era nor-)Tj
-0.0001 Tc
0.0137 Tw
(mal. Las exploraciones complementarias revelaron: VSG)'
T*
0 Tc
0.105 Tw
[(127 mm/h, hemoglobina 1)37(1 g/dl, leucocitos 3.130/ mm)]TJ
5.25 0 0 5.25 280.8396 406.0438 Tm
(3)Tj
10.5 0 0 10.5 42.5197 390.9813 Tm
-0.0001 Tc
0.316 Tw
((vn 4.000-10.000), neutr\227filos 1.010 mm)Tj
5.25 0 0 5.25 227.8409 394.5438 Tm
0 Tc
(3)Tj
10.5 0 0 10.5 236.4086 390.9813 Tm
-0.0001 Tc
(\(vn 2.000-)Tj
-18.46561 -1.09524 TD
-0.0081 Tw
(7.200\), linfocitos 1.600 \(vn 1.500-4.500\), eosin\227filos 150)Tj
0.2073 Tw
((vn 40-500), monocitos 370 (vn 400-1.100); los CD4,)'
T*
0 Tc
0.057 Tw
(CD8, plaquetas y coagulaci\227n fueron normales. Coleste-)Tj
-0.0001 Tc
0.1016 Tw
(rol total 420 mg/dl (vn 92-220), triglic\216ridos 213 mg/dl)'
T*
0 Tc
0.039 Tw
((vn 40-150), prote\222nas totales 3,9 g/dl (vn 6,4-8,3), alb\234-)Tj
-0.0001 Tc
0.065 Tw
(mina 1,9 g/dl (vn 3,5-5,2); la urea, creatinina, iones y el)'
T*
0 Tc
-0.02 Tw
(resto de la bioqu\222mica elemental estaban dentro de la nor-)Tj
-0.0001 Tc
0.4727 Tw
(malidad. Los anticuerpos antigranulocito \(IgG+IgM,)'
0 -1.09523 TD
0.0636 Tw
(citometr\222a de flujo\) fueron positivos; IgG 151 mg/dl \(vn)Tj
0 -1.09525 TD
0 Tc
0.152 Tw
(800-1.800\). Las siguientes determinaciones fueron nor-)Tj
0 -1.09523 TD
-0.0001 Tc
0.0465 Tw
(males o negativas: IgA, IgM, C3, C4, factor reumatoide,)Tj
0 -1.09524 TD
0.1151 Tw
(ANA, anti-ADN, Ro, La, RNP)Tj
12.6797 0.00001 TD
(, anti-TPO y TSH. En el)Tj
-12.6797 -1.09525 TD
0.052 Tw
(proteinograma no hab\222a bandas monoclonales. Mantoux,)Tj
0 -1.09523 TD
0.2008 Tw
(RPR, serolog\222a para virus de la hepatitis B, C y VIH)Tj
0 -1.09524 TD
0 Tc
0.054 Tw
[(negativos. Orina: proteinuria 1)37(1 g/24 h \(patr\227n glomeru-)]TJ
-0.0001 Tc
0.248 Tw
(lar no selectivo por electroforesis de alta resoluci\227n\),)'
0 -1.09523 TD
0.1035 Tw
(sedimento: 6-8 hemat\222es/c, 8-10 leucocitos/c, cultivo de)Tj
0 -1.09524 TD
0 Tc
-0.016 Tw
(orina negativo. Los ri\226ones aparec\222an normales en la eco-)Tj
T*
0.07 Tw
(graf\222a abdominal. La radiograf\222a de t\227rax y el ECG fue-)Tj
0 -1.09523 TD
0.047 Tw
(ron normales. En la biopsia renal percut\207nea se observa-)Tj
0 -1.09524 TD
-0.0001 Tc
1.0161 Tw
(ron cambios compatibles con glomerulonefritis)Tj
0.1689 Tw
(membranosa. El tr\207nsito gastrointestinal, enema opaco,)'
0 -1.09523 TD
0.0292 Tw
(TC abd\227mino-p\216lvico y la punci\227n aspiraci\227n de m\216dula)Tj
0 -1.09524 TD
0 Tw
(\227sea no mostraron hallazgos relevantes.)Tj
1.07987 -1.09524 TD
-0.015 Tc
-0.017 Tw
(La enferma se diagnostic\227 de glomerulonefritis membra-)Tj
-1.07987 -1.09523 TD
-0.0151 Tc
0.0394 Tw
(nosa y neutropenia no central autoinmune y se inici\227 trata)Tj
22.61436 0.00001 TD
0 Tc
(-)Tj
-22.61436 -1.09525 TD
-0.0151 Tc
0.0164 Tw
(miento con restricci\227n hidrosalina, furosemida 40 mg/d vo,)Tj
0 -1.09524 TD
-0.015 Tc
-0.002 Tw
(losart\207n 25 mg/d vo, ranitidina 150 mg/d vo, \207cido acetilsa-)Tj
0 -1.09523 TD
-0.0151 Tc
0.0266 Tw
(lic\222lico 100 mg/d vo y simvastatina 10 mg/d vo; el losart\207n)Tj
25.64679 61.33333 TD
0.0763 Tw
(tuvo que suspenderse por hipotensi\227n y disminuci\227n de la)Tj
0 -1.09524 TD
0 Tw
(diuresis. )Tj
1.07986 -1.09523 TD
-0.0217 Tw
(Seis meses despu\216s persist\222an los edemas y la proteinuria)Tj
-1.07986 -1.09524 TD
-0.0246 Tw
(masiva; los neutr\227filos en las sucesivas revisiones oscilaban)Tj
0.092 Tw
(entre 930 y 2.000/mm)'
5.25 0 0 5.25 404.2924 659.0438 Tm
0 Tc
(3)Tj
10.5 0 0 10.5 406.8386 655.4813 Tm
-0.015 Tc
(. Se decidi\227 tratamiento inmunosu-)Tj
-9.05025 -1.09523 TD
0.014 Tw
(presor; comentadas con la paciente las alternativas terap\216u-)Tj
0 -1.09524 TD
-0.001 Tw
(ticas y dada su neutropenia de base, se opt\227 por iniciar tera-)Tj
0 -1.09523 TD
-0.0151 Tc
0.0114 Tw
(pia con ciclosporina A neoral a dosis de unos 2,5 mg/kg/24)Tj
0 -1.09524 TD
-0.0114 Tw
(h (100 mg/12 h). La paciente refiri\227, 5 d\222as despu\216s, cefalea)Tj
0.1451 Tw
(holocraneal intensa que aparec\222a a la hora y media de la)'
0 -1.09523 TD
0.1429 Tw
(toma de ciclosporina, y que se aliviaba parcialmente con)Tj
0 -1.09524 TD
0.071 Tw
(paracetamol. La enferma no ten\222a antecedentes de cefalea.)Tj
T*
-0.015 Tc
0.019 Tw
(No hab\222a signos de focalidad neurol\227gica y los pulsos tem-)Tj
0 -1.09523 TD
-0.0151 Tc
0.195 Tw
(porales eran patentes. Los niveles de ciclosporina A, en)Tj
0 -1.09524 TD
0.0065 Tw
(sangre total, fueron 150,39 ng/ml \(rango considerado como)Tj
0 -1.09523 TD
0.1352 Tw
(terap\216utico 120-200\), magnesio s\216rico 2,2 mg/dl \(vn 1,9-)Tj
0 -1.09525 TD
0.2122 Tw
(2,5\); el resto de los par\207metros anal\222ticos no mostraban)Tj
0 -1.09523 TD
0.0545 Tw
(cambios sustanciales. En la TC craneal no se evidenciaron)Tj
0 Tw
(alteraciones. )'
1.46636 -1.09524 TD
0.1515 Tw
(La dosis de ciclosporina se redujo progresivamente a)Tj
-1.46636 -1.09524 TD
0.0783 Tw
(1,25 mg/kg/24 h (50 mg/12 h) y los niveles disminuyeron)Tj
0.1908 Tw
(hasta 62,9 ng/ml, pese a lo cual persist\222a la cefalea que)'
0.081 Tw
(interfer\222a con su actividad normal. Se baraj\227 la utilizaci\227n)'
T*
-0.015 Tc
0.069 Tw
(de otros analg\216sicos, pero a petici\227n de la enferma se sus-)Tj
-0.0151 Tc
0.0551 Tw
(pendi\227 la ciclosporina a los 16 d\222as de su inicio; la cefalea)'
0 Tw
(desapareci\227 3-4 d\222as despu\216s sin recurrir posteriormente. )'
ET
BT
/F2 1 Tf
10.5 0 0 10.5 311.811 379.4813 Tm
-0.0002 Tc
(COMENT)Tj
4.5603 0 TD
-0.0001 Tc
(ARIO)Tj
ET
BT
/F0 1 Tf
10.5 0 0 10.5 323.1496 356.4813 Tm
0 Tc
0.118 Tw
[(La ciclosporina es un polip\216ptido de 1)37(1 amino\207cidos)]TJ
-1.07986 -1.09524 TD
-0.0001 Tc
0.0907 Tw
(de naturaleza lip\227fila, que presenta concentraciones ele)Tj
22.61436 0 TD
0 Tc
(-)Tj
-22.61436 -1.09524 TD
-0.0001 Tc
0.02 Tw
(vadas a nivel del tejido adiposo y se une en un 80% a las)Tj
0.0893 Tw
(lipoprote\222nas, pero con una pobre y err\207tica penetraci\227n)'
T*
0 Tc
0.065 Tw
(al sistema nervioso central. La ciclosporina es metaboli-)Tj
-0.0001 Tc
0.1039 Tw
(zada por el citocromo P450 3 A, con excreci\227n biliar y)'
0 -1.09523 TD
0.2363 Tw
(recirculaci\227n enterohep\207tica. Los efectos adversos son)Tj
0 -1.09525 TD
0.1057 Tw
(generalmente dependientes de la dosis y responden a la)Tj
0 -1.09523 TD
0.1505 Tw
(disminuci\227n de la misma, siendo los m\207s frecuentes el)Tj
0 -1.09524 TD
0.2281 Tw
(deterioro de la funci\227n renal y hep\207tica, hipertricosis,)Tj
T*
0 Tc
-0.008 Tw
(temblores, hipertensi\227n arterial, hipertrofia gingival, tras-)Tj
0 -1.09523 TD
-0.0001 Tc
0.441 Tw
(tornos gastrointestinales \(n\207usea, v\227mitos, diarrea y)Tj
0 -1.09524 TD
0.0809 Tw
(malestar digestivo\), sensaci\227n de quemaz\227n en manos y)Tj
0.1829 Tw
(pies, y alteraciones electrol\222ticas como hipercaliemia e)'
0 -1.09523 TD
(hipomagnesemia.)Tj
1.31361 -1.09524 TD
-0.015 Tc
-0.001 Tw
(Pese a su irregular paso a trav\216s de la barrera hematoen-)Tj
-1.31361 -1.09524 TD
-0.0151 Tc
0.031 Tw
(cef\207lica, la ciclosporina es un f\207rmaco que provoca efectos)Tj
0 -1.09523 TD
0.1228 Tw
(secundarios neurol\227gicos en aproximadamente el 40% de)Tj
0 -1.09524 TD
0.1394 Tw
(pacientes (5). El m\207s frecuente es el temblor)Tj
18.02931 0.00001 TD
(, tambi\216n se)Tj
-18.02931 -1.09525 TD
0.0291 Tw
(han descrito reacciones neurot\227xicas leves como agitaci\227n,)Tj
0 -1.09523 TD
0.0532 Tw
(insomnio, ansiedad y amnesia. Como efectos neurot\227xicos)Tj
0 -1.09524 TD
0.2679 Tw
(severos asociados a la ciclosporina se han comunicado)Tj
T*
-0.015 Tc
0.085 Tw
(casos de confusi\227n, desorientaci\227n, alucinaciones, convul-)Tj
0 -1.09523 TD
-0.0151 Tc
0.0079 Tw
(siones, leucoencefalopat\222a posterior)Tj
13.73425 0.00001 TD
(, neuropat\222a perif\216rica y)Tj
-13.73425 -1.09525 TD
0.0939 Tw
(s\222ndromes extrapiramidales (6). Se han descrito diferentes)Tj
0 -1.09524 TD
0.1816 Tw
(factores de riesgo que pueden favorecer el desarrollo de)Tj
0 -1.09523 TD
0.116 Tw
(neurotoxicidad, entre los que se encuentra la hipertensi\227n)Tj
7 0 0 7 42.5197 744.001 Tm
0 Tc
0 Tw
(Vol. 28. N.)Tj
4.47167 0.00001 TD
[<A1>-250(6, 2004)-4754(CEFALEA ASOCIADA A CICLOSPORINA EN UN PACIENTE CON GLOMERULONEFRITIS MEMBRANOSA)]TJ
8 0 0 8 540.7559 744.001 Tm
(455)Tj
ET
0 0 0 0 k
42.744 18.126 25.512 15.007 re
f
BT
/F0 1 Tf
8 0 0 8 42.7441 19.8606 Tm
0 0 0 1 k
(83)Tj
ET
Q
endstream
endobj
5 0 obj
<<
/Length 10077
>>
stream
/GS0 gs
q
0 0.701 595 793 re
W n
1 g
0 793.701 0 0 re
f
Q
/GS0 gs
/GS2 gs
0 0 0 0 k
42.52 51.024 510.236 657.638 re
f
q
BT
/F0 1 Tf
10.5 0 0 10.5 42.5197 701.4813 Tm
0 Tr
0 0 0 1 k
-0.0151 Tc
-0.0145 Tw
(arterial, la hipomagnesemia, y la hipocolesterolemia (6). En)Tj
0 -1.09524 TD
-0.015 Tc
0.097 Tw
(la paciente que describimos la tensi\227n arterial estaba con-)Tj
0 -1.09523 TD
-0.0151 Tc
0.1212 Tw
(trolada, el magnesio s\216rico era normal y el colesterol por)Tj
0 -1.09524 TD
0 Tw
(encima del rango habitual.)Tj
1.07987 -1.09524 TD
-0.0001 Tc
0.0616 Tw
(La cefalea de intensidad leve puede aparecer hasta en)Tj
-1.07987 -1.09523 TD
0.005 Tw
(un 20-37% de los pacientes tratados con ciclosporina (7).)Tj
0 -1.09524 TD
0 Tc
-0.02 Tw
[(Sin embar)18(go, la cefalea intensa e incapacitante que obliga)]TJ
0 -1.09523 TD
-0.014 Tw
(a disminuir su dosis o suspenderla tiene una baja frecuen-)Tj
0 -1.09524 TD
-0.0001 Tc
0.1095 Tw
(cia (8) y se ha descrito tanto en pacientes trasplantados)Tj
T*
0 Tc
-0.008 Tw
[(\(9,10\) como en no trasplantados \(1)37(1\). En la tabla I se pre-)]TJ
0 -1.09523 TD
0.002 Tw
(sentan los casos cl\222nicos de cefalea intensa e incapacitan-)Tj
0 -1.09524 TD
-0.0001 Tc
0 Tw
(te descritos en la literatura m\216dica (9,12,13).)Tj
1.07987 -1.09524 TD
-0.0151 Tc
0.2501 Tw
(El mecanismo patog\216nico de la cefalea inducida por)Tj
-1.07987 -1.09523 TD
0.0624 Tw
(ciclosporina es desconocido y no se encuentra relacionado)Tj
0 -1.09524 TD
-0.015 Tc
0.03 Tw
(con niveles sangu\222neos t\227xicos. Se postula que la ciclospo-)Tj
0 -1.09523 TD
-0.0151 Tc
0.0999 Tw
(rina podr\222a tener un efecto vasoactivo y de proagregaci\227n)Tj
0 -1.09525 TD
-0.0203 Tw
(plaquetaria que disminuir\222a el flujo sangu\222neo cerebral (14).)Tj
0 -1.09523 TD
-0.015 Tc
0.103 Tw
(La ciclosporina incrementa el ADP que induce la agrega-)Tj
-0.0151 Tc
0.2669 Tw
(ci\227n plaquetaria y libera tromboxano A)'
5.25 0 0 5.25 215.8554 492.3814 Tm
0 Tc
(2)Tj
10.5 0 0 10.5 218.4016 494.4814 Tm
-0.0151 Tc
(, act\234a adem\207s)Tj
-16.75066 -1.09524 TD
0.1119 Tw
(sobre las c\216lulas endoteliales inhibiendo la producci\227n de)Tj
T*
-0.015 Tc
-0.005 Tw
(prostaciclina. Como consecuencia de estos efectos, se redu-)Tj
-0.0151 Tc
0.0447 Tw
(cir\222a el calibre arterial y el flujo sangu\222neo cerebral y renal)'
0 Tw
(en pacientes tratados con este inmunosupresor (15).)'
1.07987 -1.09524 TD
-0.0001 Tc
-0.0211 Tw
(La cefalea asociada a la administraci\227n de ciclosporina)Tj
-1.07987 -1.09524 TD
0.1128 Tw
(no responde a un tratamiento analg\216sico cl\207sico para el)Tj
-0.0232 Tw
(dolor de cabeza, ni al empleo de amitriptilina o verapami)'
22.61436 0 TD
0 Tc
(-)Tj
-22.61436 -1.09524 TD
0.014 Tw
(lo (6). Asimismo, tampoco parece que desarrolle toleran-)Tj
-0.0001 Tc
0.047 Tw
(cia contrariamente a lo descrito con otros f\207rmacos (16).)'
0.0724 Tw
(Gryn y cols., estudiaron el efecto del empleo de propra)'
22.61437 0 TD
0 Tc
(-)Tj
-22.61437 -1.09524 TD
-0.0001 Tc
0.0458 Tw
(nolol 20 mg/6-8 h en pacientes con cefalea asociada a la)Tj
0.1359 Tw
(administraci\227n de ciclosporina, desapareciendo el dolor)'
25.64679 32.85714 TD
0.049 Tw
(de cabeza en 4 de los 7 pacientes incluidos en el estudio)Tj
0 -1.09524 TD
0 Tc
0.025 Tw
[((10). Sin embar)18(go, este betabloqueante no ha sido efecti-)]TJ
0 -1.09523 TD
-0.0001 Tc
0.023 Tw
(vo en otras ocasiones (8,12). Parece que el sumatriptan o)Tj
0 -1.09524 TD
0 Tc
0.209 Tw
[(los er)18(gotam\222nicos son otras opciones terap\216uticas para)]TJ
-0.0001 Tc
0.2361 Tw
(aliviar la cefalea inducida por ciclosporina (8,12). En)'
0 -1.09523 TD
0.3124 Tw
(nuestra paciente, la existencia concomitante de asma)Tj
0 -1.09524 TD
0.1302 Tw
(bronquial contraindicaba el empleo de betabloqueantes;)Tj
0 -1.09523 TD
0 Tc
0.179 Tw
[(por otra parte el sumatriptan y la er)18(gotamina no est\207n)]TJ
0 -1.09524 TD
-0.008 Tw
(desprovistos de efectos adversos y por decisi\227n de la pro-)Tj
-0.0001 Tc
0 Tw
(pia enferma se suspendi\227 la ciclosporina.)'
1.07986 -1.09523 TD
0 Tc
0.026 Tw
(En el presente caso son varias las evidencias que indi-)Tj
-1.07986 -1.09524 TD
-0.0001 Tc
0.0183 Tw
(can la relaci\227n entre la ciclosporina y la cefalea intensa e)Tj
T*
0 Tc
0.115 Tw
[(incapacitante. En primer lugar)40(, existe una relaci\227n tem-)]TJ
0 -1.09523 TD
-0.0001 Tc
0.0223 Tw
(poral entre la aparici\227n de los s\222ntomas neurol\227gicos con)Tj
0 -1.09524 TD
0 Tc
0.003 Tw
[(el inicio de la terapia con ciclosporina. En segundo lugar)40(,)]TJ
0 -1.09523 TD
-0.009 Tw
(otras potenciales causas de cefalea se descartaron razona-)Tj
0 -1.09525 TD
-0.014 Tw
[(blemente. En tercer lugar)40(, cuando la dosis de ciclosporina)]TJ
0 -1.09523 TD
-0.0001 Tc
0.0708 Tw
(fue reducida a la mitad, la cefalea persisti\227 y no remiti\227)Tj
T*
0 Tc
0.18 Tw
[(hasta que se suspendi\227 el inmunosupresor)55(. Adem\207s, la)]TJ
0 -1.09524 TD
0.06 Tw
(ciclosporina fue el \234nico f\207rmaco que se a\226adi\227 al trata-)Tj
0 -1.09523 TD
-0.004 Tw
(miento de la paciente antes de que se desarrollar\207 la cefa-)Tj
0 -1.09524 TD
-0.0001 Tc
0.0051 Tw
(lea intensa e incapacitante. La imputabilidad de la ciclos)Tj
22.61439 0 TD
0 Tc
(-)Tj
-22.61439 -1.09524 TD
-0.0001 Tc
0.017 Tw
(porina con este efecto neurot\227xico se analiz\227 a trav\216s del)Tj
0.1486 Tw
(m\216todo de estimaci\227n de la probabilidad de reacciones)'
0.1086 Tw
(adversas a medicamentos de Naranjo, obteni\216ndose una)'
0 Tw
(relaci\227n de causalidad de probable (17).)'
1.07986 -1.09524 TD
0.0958 Tw
(Este caso ilustra un efecto adverso de la ciclosporina)Tj
-1.07986 -1.09524 TD
0.1961 Tw
(que es importante conocer por la repercusi\227n sobre la)Tj
0.0398 Tw
(calidad de vida que ocasiona, que puede comprometer la)'
0.0507 Tw
(adherencia al tratamiento y que puede hacer necesaria la)'
0 Tw
(suspensi\227n del f\207rmaco.)'
8 0 0 8 42.5197 744.001 Tm
0 Tc
(456)Tj
7 0 0 7 255.1593 744.001 Tm
-0.0001 Tc
(J. BORR\347S BLASCO ET AL.)Tj
34.0434 0.00001 TD
0 Tc
(F)Tj
5.25 0 0 5.25 497.3545 744.001 Tm
-0.0001 Tc
(ARM)Tj
7 0 0 7 511.0631 744.001 Tm
0 Tc
(H)Tj
5.25 0 0 5.25 516.1166 744.001 Tm
-0.0001 Tc
(OSP)Tj
7 0 0 7 527.4937 744.001 Tm
-0.0002 Tc
((Madrid))Tj
ET
0 0 0 0 k
527.244 18.126 25.512 16.673 re
f
BT
/F0 1 Tf
8 0 0 8 544.7559 19.8606 Tm
0 0 0 1 k
0 Tc
(84)Tj
ET
0 0 0 0 k
42.52 57.701 510.236 291.657 re
f
0 J 0 j 0.4 i 10 M []0 d 0.5 w 
0 0 0 1 K
42.52 316.176 m
552.756 316.176 l
S
BT
/F17 1 Tf
8.5 0 0 8.5 150.5656 320.6779 Tm
0 0 0 1 k
-0.0002 Tc
(Tabla I. )Tj
ET
BT
/F18 1 Tf
8.5 0 0 8.5 181.7412 320.6779 Tm
-0.0001 Tc
(Casos cl\222nicos de cefalea intensa e incapacitante descritos en la literatura)Tj
ET
BT
/F19 1 Tf
7.225 0 0 8.5 42.5197 306.6779 Tm
0 Tc
[(Referencia)-3946(Pacientes)-2034(Edad)-1626(Sexo (M/F))-2286(Diagn\227stico)-2672(Dosis)-4898(Niveles )-6267(Tratamiento)]TJ
33.06209 -1.17647 TD
-0.0001 Tc
(ciclosporina)Tj
7.12 0.00001 TD
(sangu\222neos)Tj
ET
42.52 282.176 m
552.756 282.176 l
S
BT
/F19 1 Tf
7.225 0 0 8.5 332.8353 286.6779 Tm
(ciclosporina)Tj
ET
BT
/F18 1 Tf
7.225 0 0 8.5 42.5197 272.6779 Tm
0 Tc
[(Steiger et al., )-4196(1)-4228(48)-4126(F)-4286(Trasplante)-3283(400 mg/d)-2952(Dentro del \207mbito)-1712(Mantuvo dosis de ciclosporina, siendo no)]TJ
0.5559 -1.17647 TD
-0.0001 Tc
(1994 (12))Tj
24.83441 0.00001 TD
(hep\207tico)Tj
14.5137 0.00001 TD
0 Tc
0.191 Tw
[(terap\216utico)-5212(efectivo el tratamiento con pizotifeno, propra)-1(-)]TJ
10.04408 -1.17648 TD
-0.0001 Tc
0 Tw
(nolol y amitriptilina. S\222 mejor\227 con sumatriptan )Tj
-39.86521 -1.17647 TD
0 Tc
[(2)-4228(59)-4126(F)-4286(Trasplante)-3284(400 mg/d)-2952(Dentro del \207mbito)-1712(Disminuy\227 la dosis a 350 mg/d, siendo no )]TJ
15.30742 -1.17647 TD
-0.0001 Tc
(hep\207tico)Tj
14.79178 0.00001 TD
(terap\216utico)Tj
10.04282 0.00001 TD
0.0947 Tw
(efectivo el tratamiento con analg\216sicos y ergo)Tj
20.06324 0.00001 TD
0 Tc
(-)Tj
-20.06324 -1.17649 TD
-0.0001 Tc
0 Tw
(tamina. S\222 mejor\227 con sumatriptan)Tj
-40.14202 -1.17647 TD
0 Tc
[(3)-4228(59)-4126(F)-4286(Trasplante )-3006(Disminuye)-2732(Dentro del \207mbito)-1712(Disminuy\227 la dosis a 125 mg/d, siendo efectivo)]TJ
15.30742 -1.17646 TD
[(hep\207tico)-4006(dosis inicial )-2065(terap\216utico)-5213(el tratamiento con paracode\222na)]TJ
ET
42.52 188.176 m
552.756 188.176 l
S
BT
/F18 1 Tf
7.225 0 0 8.5 281.3933 192.6779 Tm
-0.0001 Tc
(a 125 mg/d)Tj
-33.06209 -1.64706 TD
(Rozen et al.,1996 (8))Tj
10.08289 0.00001 TD
0 Tc
(1)Tj
4.78383 0.00001 TD
-0.0002 Tc
(35)Tj
5.23759 0.00001 TD
0 Tc
(F)Tj
4.73009 0.00001 TD
-0.0001 Tc
(Trasplante)Tj
7.67176 0.00001 TD
-0.0002 Tc
(n.d.)Tj
7.12 0.00001 TD
0 Tc
[(Dentro del \207mbito)-1712(Mantuvo dosis de ciclosporina, siendo no efectivo )]TJ
-14.23586 -1.17651 TD
-0.0001 Tc
(hep\207tico)Tj
14.79178 0.00001 TD
(terap\216utico)Tj
10.04282 0.00001 TD
-0.009 Tw
(el tratamiento con AINE, propranolol, verapami)Tj
20.06324 0.00001 TD
0 Tc
(-)Tj
-20.06324 -1.17649 TD
-0.0001 Tc
0.0335 Tw
(lo y amitriptilina. S\222 mejor\227 con sumatriptan. Se)Tj
ET
42.52 144.176 m
552.756 144.176 l
S
BT
/F18 1 Tf
7.225 0 0 8.5 405.3947 148.6779 Tm
0 Tw
(sustituy\227 la ciclosporina por tacrolimus)Tj
-50.22492 -1.64706 TD
0 Tc
[(Maghrabi y Bohlega )-1249(1)-4228(25)-4125(F)-4287(Trasplante renal)-895(n.d.)-5452(Dentro del \207mbito)-1712(Se retir\227 la ciclosporina por tacrolimus)]TJ
0.5559 -1.17646 TD
-0.0001 Tc
(1998 (13))Tj
39.62619 0.00001 TD
(terap\216utico)Tj
-30.0992 -1.17648 TD
0 Tc
(2)Tj
4.78383 0.00001 TD
-0.0002 Tc
(26)Tj
5.23759 0.00001 TD
0 Tc
[(F)-4286(Trasplante renal)-895(n.d.)-5453(Dentro del \207mbito)-1712(Mantuvo dosis de ciclosporina, siendo no efectivo)]TJ
20.07777 -1.17649 TD
0.462 Tw
[(terap\216utico)-5211(el tratamiento con antidepresivos tric\222clicos,)]TJ
10.04282 -1.17647 TD
-0.0001 Tc
0 Tw
(ergotamina y sumatriptan)Tj
-40.14202 -1.17647 TD
0 Tc
[(3)-4228(30)-4126(F)-4286(Trasplante renal)-895(n.d.)-5453(Dentro del \207mbito )-1434(n. d.)]TJ
ET
42.52 70.176 m
552.756 70.176 l
S
BT
/F18 1 Tf
7.225 0 0 8.5 332.8353 74.6779 Tm
-0.0001 Tc
(terap\216utico)Tj
7 0 0 7 42.5197 62.6779 Tm
(n. d.: no descrito.)Tj
ET
Q
endstream
endobj
6 0 obj
<<
/Length 5029
>>
stream
/GS0 gs
q
0 0.701 595 793 re
W n
1 g
0 793.701 0 0 re
f
Q
/GS0 gs
/GS2 gs
0 0 0 0 k
42.52 51.024 510.236 657.638 re
f
q
BT
/F0 1 Tf
7 0 0 7 42.5197 744.001 Tm
0 Tr
0 0 0 1 k
(Vol. 28. N.)Tj
4.47167 0.00001 TD
[<A1>-250(6, 2004)-4754(CEFALEA ASOCIADA A CICLOSPORINA EN UN PACIENTE CON GLOMERULONEFRITIS MEMBRANOSA)]TJ
8 0 0 8 540.7559 744.001 Tm
(457)Tj
ET
0 0 0 0 k
42.744 18.126 25.512 15.007 re
f
BT
/F0 1 Tf
8 0 0 8 42.7441 19.8606 Tm
0 0 0 1 k
(85)Tj
ET
0 J 0 j 0.4 i 10 M []0 d 0.5 w 
0 0 0 1 K
42.52 694.796 m
552.756 694.796 l
S
BT
/F2 1 Tf
10.5 0 0 10.5 42.5197 700.7149 Tm
-0.0002 Tc
(Bibliograf\222a)Tj
ET
0 0 0 0 k
42.52 462.606 510.236 218.749 re
f
BT
/F0 1 Tf
8 0 0 8 46.5197 675.8838 Tm
0 0 0 1 k
0 Tc
0.085 Tw
[(1.)-1000(Horton S, Resman-Targoff BH, Thompson DF. Use of cyclosporine)]TJ
1.75 -1.12125 TD
-0.0001 Tc
0 Tw
(in rheumatoid arthritis. Ann Pharmacother 1993; 27: 44-6. )Tj
-1.75 -1.12125 TD
0 Tc
-0.015 Tw
[(2.)-1000(Dunn CJ, Wagstaff AJ, Perry CM, Plosker GL, Goa KL. Cyclosporin:)]TJ
1.75 -1.12125 TD
-0.0001 Tc
-0.0111 Tw
(an updated review of the pharmacokinetic properties, clinical efficacy)Tj
0.2486 Tw
(and tolerability of a microemulsion-based formulation (neoral) in)'
0 Tw
(organ transplantation. Drugs 2001; 61: 1957-2016. )'
-1.75 -1.12125 TD
0 Tc
0.033 Tw
[(3.)-1000(Bennett WM. Insights into chronic cyclosporine nephrotoxicity. Int J)]TJ
1.75 -1.12125 TD
-0.0001 Tc
0 Tw
(Clin Pharmacol Ther 1996; 34: 515-9. )Tj
-1.75 -1.12125 TD
0 Tc
0.093 Tw
[(4.)-1000(Philip AT, Gerson B. Toxicology and adverse effects of drugs used)]TJ
1.75 -1.12125 TD
-0.0001 Tc
0.0016 Tw
(for immunosuppression in organ transplantation. Clin Lab Med 1998;)Tj
0 Tc
0 Tw
(18: 755-65. )'
-1.75 -1.12125 TD
0.134 Tw
[(5.)-1000(Wijdicks EF, Wiesner RH, Krom RA. Neurotoxicity in liver trans-)]TJ
1.75 -1.12125 TD
-0.0001 Tc
0.2529 Tw
(plant recipients with cyclosporine immunosuppression. Neurology)Tj
0 Tc
0 Tw
(1995; 45: 1962-4. )'
-1.75 -1.12125 TD
0.023 Tw
[(6.)-1000(Gijtenbeek JM, van den Bent MJ, Vecht CJ. Cyclosporine neurotoxi-)]TJ
1.75 -1.12125 TD
-0.0001 Tc
0 Tw
(city: a review. J Neurol 1999; 246: 339-46. )Tj
-1.75 -1.12124 TD
0 Tc
0.131 Tw
[(7.)-1000(Reece DE, Frei-Lahr DA, Shepherd JD, Dorovini-Zis K, Gascoyne)]TJ
1.75 -1.12125 TD
-0.0001 Tc
0.1346 Tw
(RD, Graeb DA, et al. Neurologic complications in allogeneic bone)Tj
0.3733 Tw
(marrow transplant patients receiving cyclosporin. Bone Marrow)'
0 Tw
(Transplant 1991; 8: 393-401. )'
-1.75 -1.12125 TD
0 Tc
0.031 Tw
[(8.)-1000(Rozen TD, Wijdicks EF, Hay JE. Treatment-refractory cyclosporine-)]TJ
1.75 -1.12125 TD
-0.0001 Tc
0.1891 Tw
(associated headache: relief with conversion to FK-506. Neurology)Tj
0 Tc
0 Tw
(1996; 47: 1347. )'
-1.75 -1.12125 TD
(9.)Tj
1.75 0 TD
-0.0001 Tc
0.0795 Tw
(de Groen PC, Aksamit AJ, Rakela J, Forbes GS, Krom RA. Central)Tj
33.66142 25.78874 TD
0 Tc
-0.007 Tw
(nervous system toxicity after liver transplantation. The role of cyclos-)Tj
0 -1.12125 TD
-0.0001 Tc
0 Tw
(porine and cholesterol. N Engl J Med 1987; 317: 861-6. )Tj
-2.25 -1.12125 TD
0 Tc
0.024 Tw
[(10.)-1000(Gryn J, Goldberg J, Viner E. Propranolol for the treatment of cyclos-)]TJ
2.25 -1.12125 TD
-0.0001 Tc
0 Tw
(porine-induced headaches. Bone Marrow Transplant 1992; 9: 211-2. )Tj
-2.25 -1.12125 TD
0 Tc
0.051 Tw
[(11.)-1000(Fradin MS, Ellis CN, Voorhees JJ. Management of patients and side)]TJ
2.25 -1.12125 TD
-0.0001 Tc
0.1899 Tw
(effects during cyclosporine therapy for cutaneous disorders. J Am)Tj
0 Tw
(Acad Dermatol 1990; 23: 1265-73.)'
-2.25 -1.12125 TD
0 Tc
0.024 Tw
[(12.)-1000(Steiger MJ, Farrah T, Rolles K, Harvey P, Burroughs AK. Cyclospo-)]TJ
2.25 -1.12125 TD
-0.0001 Tc
0.1897 Tw
(rin associated headache. J Neurol Neurosurg Psychiatry 1994; 57:)Tj
0 Tc
0 Tw
(1258-9. )'
-2.25 -1.12125 TD
0.058 Tw
[(13.)-1000(Maghrabi K, Bohlega S. Cyclosporine-induced migraine with severe)]TJ
2.25 -1.12125 TD
-0.0001 Tc
0.159 Tw
(vomiting causing loss of renal graft. Clin Neurol Neurosurg 1998;)Tj
0 Tc
0 Tw
(100: 224-7. )'
-2.25 -1.12125 TD
0.069 Tw
[(14.)-1000(Toung TJ, Bunke FJ, Grayson RF, Kontos GJ, Fraser CD Jr, Baum-)]TJ
2.25 -1.12125 TD
-0.0001 Tc
0.0121 Tw
(gartner WA, et al. Effects of cyclosporine on cerebral blood flow and)Tj
0 Tw
(metabolism in dogs. Transplantation 1992; 53: 1082-8. )'
-2.25 -1.12124 TD
0 Tc
0.032 Tw
[(15.)-1000(Morris R. Modes of action of FK506, cyclosporin A, and rapamycin.)]TJ
2.25 -1.12125 TD
-0.0001 Tc
0 Tw
(Transplant Proc 1994; 26: 3272-5. )Tj
-2.25 -1.12125 TD
0 Tc
-0.004 Tw
[(16.)-1000(Christiansen I, Iversen HK, Olesen J. Headache characteristics during)]TJ
2.25 -1.12125 TD
0.042 Tw
(the development of tolerance to nitrates: pathophysiological implica-)Tj
-0.0001 Tc
0 Tw
(tions. Cephalalgia 2000; 20: 437-44.)'
-2.25 -1.12125 TD
0 Tc
0.059 Tw
[(17.)-1000(Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et)]TJ
2.25 -1.12125 TD
-0.0001 Tc
0.0156 Tw
(al. A method for estimating the probability of adverse drug reactions.)Tj
0 Tw
(Clin Pharmacol Ther 1981; 30: 239-45.)'
ET
Q
endstream
endobj
7 0 obj
<<
/Nums[0<</S/D>>]
>>
endobj
8 0 obj
<<
/Differences[32/space 37/percent 40/parenleft/parenright 43/plus/comma/hyphen/period/slash/zero/one/two/three/four/five/six/seven/eight/nine/colon/semicolon 64/at/A/B/C/D/E/F/G/H/I/J/K/L/M/N/O/P/Q/R/S/T/U/V/W 90/Z 97/a/b/c/d/e/f/g/h/i/j/k/l/m/n/o/p/q/r/s/t/u/v/w/x/y/z 135/aacute 142/eacute 146/iacute 150/ntilde/oacute 154/odieresis 156/uacute 161/degree 213/quoteright 231/Aacute 234/Iacute 238/Oacute]
/BaseEncoding/MacRomanEncoding
/Type/Encoding
>>
endobj
9 0 obj
<<
/Length1 9367
/Length 9367
/Subtype/Type1C
>>
stream
  LWLOVH+Times-Roman   @¯ ¯¯¯¯˚<˚n˙|˙
 ãã
 ãã   ˚   ˜  §¨  $v }àç002.000Copyright © 1994-1997 Stream Technologies Inc. All Rights Reserved.
 Turku is a trademark of Stream Technologies Inc.Turku RomanTurku  S    - B  D J M P T Q S O F V œ U E  N » C I H & ÿ G  K  R W Z *   5 ) [ Y ” 4 ⁄  	 
 ◊ + # 0 3 ´ " $ / ∂ 2 6 ; ' . ª 7 ( %     ! 1      ﬁ  L  ° 8 , X U   à Î1ø¿h†Âto‰B¨5Å˘2‰ùˇ	m
7
¥&Éö?¨Öº+w‚!™é@~ø~∆eº2≈&èÔV◊=|ÍT‹8ØÅΩ7p,¢c~´Ø⁄_ . i!!å"$˚*~ß˘ß√÷F’˜o–T◊‘¯Q˜0ÿiª˚ÊÿÓ¡ÆµŒﬁC≈#!;H0J¢iÒ4‰˚<ulG&ÿI˜	˜
ÿÕÚÿ1¯PuiCVTØEø‘ƒ∏≥ œ∂_G‰ô¸-G__IAU«›Œû±…æ™tîÑãËE£rN˚*~•˘•£Î˜òÎ¯p˜ﬂ˜c˜E∆§ndò[[d~rnFPb˚˚˚≥˚—Or®≤~ªª≤ò§®—«≥˜˜+˚h`!44`ı˜h˜i∂ı‚‚∂!˚idã≤dû˘ûÓ∞¯Ë˜Bs˚
Siz˚I0Åè∞¯n”òò’èü˚ßw’áò~C¸QpC~~Aáw¯≠˚bñvåƒ¯§∞„˜6›x¯O≥•{tÖà}rÖóª˜W˜`π˚ 1CYNrûw¢¢°†°òáòãò®™ü∑π¶lWNOuBqWg]kxjãZãN∑`…ã∏ã∏¢¬Ω∏Tëùx∑™ßõ≠ß˚0ﬂsàÄÉx{yb{sfo≠π»∫µ˜±˚bÅ”¯®§◊¯0˜(}ì`HapQã1K›˜ƒ‘ÿ≤ñÇcóëwïkö|£ã¶ûù•¡E∫<˚+!˚!˚⁄/˜ﬂ∆∫˜¿¸†v¯^w˜$◊8ﬂ˜E˘ßt¢opttop°tßß¢¢¶÷˝õËKèÅñ”˜˜ÜèWwZyVy|é©åãì¶î{_˚{CÅGà{¸†vÏﬂ˜îõMå~ó√¯ÁáéHwvÖEy{åôíãó∞ìÄY¸pV{}Ná{˚*Ç¶¯4ß®‰˜ö‰¯i˜~˜0È˚˚0+˚˚Á'˜˜ÍÛ˜2h˚^FA8O˜˜*ÁºÃ–ﬂ«*˚˚ôÇ°êv¯Zwí¢æ»˜:—ú˜˜ªt´M∞ Ànú|§ã©Ø≠®∂≈Æd6úõ¨á˜ÉÜáâÖÜÑåéÖúôcçs:QXDO™e·Z≈j≠xùqãn_koYEiØÚs{\˚/òîíêéîìïäàñúÅ¥§á•Ÿ ƒ”˚*˚Vv˜a´¯«åw’ﬂ˜v‡Ï¯i˜à˜F‰*R_sVaâç‘‹ÖéTvää4m{åóéãó´ëÅ[¸gUÑÑMÑ{˜ÖõAå}ó…˜0m´©≤˜Ê˜˜$6f˚YAArmóûs}óÇóï˜äÏØìª™∫’º>˚˚—†v¯`w†w÷ﬂ–˜‚¯+¨wühblsH]â‰∞ÜéJqwÑMu{éöìåï§ï{_˚éYÇÉNÅ{˜ÉõKvùƒ˜súò§ûûôòôìîíìáÉîx†ìáõ°õû•˚*†v¯)¬åw⁄‹:ﬂ˜Eﬂ‘¯xõ]}õº˜yË^ƒB[p|ID€¨ÑçYxà@tyéôëåì¶ì{[˚ãS}z\â{˜göYê{ò≠˜≠Ãª√õî¨ª£kJ˚eN}xZà{˚bÅ–˜o´˜Ø§–F“˜cÒÙ¯<˜1{ìW<dpJã.Pﬁ˜Ö˜À˜P…&˚7(˚&˚ —6˜	ÎÕø˜ΩÏ˚˜-˚cŸöÆØ«∆•m7ó˚*Åƒ¯(w—ﬂ˜Fﬂ=ŸË¯rØôYäñ∫˜Ï˚2{ÀáïÇY˚ÅràÄÉÅuy^wlcjÆµ˜€˚%{ªàò~[˚è;∫Y◊Ø±õ¶¶Ë∑∂9çàŸßîéæô˚bÅ–˜o´˜Ø§–F“¿˜rGÒ√˜œ˘ú}ôz|}Ñ||˚'˚)≥˜.Ïûóîôãú¸˝Ú¯<˜1{ìW<dpJã.Pﬁ˜Ö˜À˜P…&˚7(˚&˚ —6˜	ÎÕø˜ΩÍ˚˜-˚cŸöÆØ«∆•m7ó¸Åø¯´–ﬂ˜™Õ~ñvrzÅtãg|¶ ˜≥´&˜ñâéÖU<midpÑÜâàãÖãáåâéãø˚¬5©b…∏≤§æ¨˚*Åø¯ß¶·˜wﬂ¯µõÉÇäãáfÇó∏¯ÀÜéUx|á=v{åòëãêØìÇa˚0¨crïb˚.˚˚˚◊2˜¿µ†∂™çNêàŸßoÅÎ≠˚+»m^l_9Sﬁ˜˜æ◊‘¬ª\U˚*†v˜i·¯ö=åyñ∫¯ÌÇç˚G0~•ïúíúèîã¢ï}j¸m\yÄ=ä|˜†v¯-øåw·ﬂ˜Lﬂ˜Kﬁ‹˘ôõRåïª˜c˜d∆=SXpSU≈xk§SbvÇXFÜáÉÜÅÉ÷ºÉéZyåã1pyéõêåñ§ïx^˚íV}}Sâ{˜rõYyô∞˜Øéïïóï‹£®´ó™ª°iC˚mU~Sà{˜sõSå|ú»˜ê∏´™ú∫¡ûn9˚gSÑÉPÑ{˚bñvåƒ¯§∞„§˜r6›ƒ˜œ˘ú}ôz|}Ñ||˚'˚)≥˜.Ïûóîôãú¸˝t¯O≥•{tÖà}rÖóª˜W˜`π˚ 1CYNrûw¢¢°†°òáòãò®™ü∑π¶lWNOuBqWg]kxjãZãN∑`…ã∏ã∏¢¬Ω¥Tëùx∑™ßõ≠ß˚0ﬂsàÄÉt{yb{sfo≠π»∫µ˜±˚*Å´¯Àœﬂ˜w‰¯h˜á˜?Ë$SWlXpâ˜¡Üéa{U{[~{åïíãèÆîÅc¸úm„i⁄˜Ú˜˜!2b˚	]L5[\££˜ê∂µ¨ƒ◊ø;˚˚*†v¯+¡”ﬂ˜Nﬂ¯zõXêÇó–˜[ˆa¿9R_rQ`â˜¬Öè\{òè kzåìëãè∞ìÇa¸kFÇUÜ{˜kõTç~úŒ˜Öπµ´ù±∫¶eF˚ZGÄ}Rá{˚*˚nƒ˜&÷@‘Ê§˜k≤êßß–nﬁ˜EŸ•®›¿¯i¯≤?u~çìwù]têm*AE-L§h–gCKyvtuö|≤{æ¿FZnfgTÿ`Ô˜˜ŸÊ ]¥@é˚êTçsïãùîòûôòóòôìîúêÜ®ÁœÕ‰®áû|∞P˚Snf_›¿MaÃÌ»¶Æªƒ∏B.Û˚ﬁR?b˚ﬁ¿3M©µ£ïú≤π¨Ñéõâ§àªâ¿âà°Äãidã±eû˜»µb¥˜ì≤xûÓ˜ú¢¨¢´Ä¯Ë˜>o˚ ^]s˚7#Åè≤˜å˜.âﬂäñÇö6¢˜|t6|Å8˚.˜q®êêß˜˜û~0ù§á˜#¸•WÄw’áò~C¸QC~~Aáw¯Ø˚*Ç¶¯4ß®‰∆˜rx‰ﬂ˜œ˘ú}ôz|}Ñ||˚'˚)≥˜.Ïûóîôãú¸#˝Ë¯i˜~˜0È˚˚0+˚˚Á'˜˜ÍÛ˜2h˚^FA8O˜˜*ÁºÃ–ﬂ«*˚˚—†v¯7´˜_®Úﬂ7ﬁ¯˘´\ßU˚QA˚2ä:k‹˚œBÅÄBá{˜òõ:çñ÷˜œ˜´Ë˚˜∆ùß≤†îÖoük°îÑú¢ûû¢˚—†v˜UÀ≤˜ä˜±˜UÀ˚äK¸˚Xv˘7w˜$Á8ﬂ˜U˘ßt¢pottop¢tß¶¢¢¶Ëå˝¯^ÜèXwXyWy|é©åãì¶î{_¸!Äjg}ÇêóÄ≥iÜéwwwywk≤t¬˜∆÷˜"õv£v√˜ †˜Xñøh≤\jrskl¢wØ`ôêéãîïêáÅäâiogVgïxŒ≠∏»ƒ˚*˚Vv˜a…¯ß£‡˜|ﬂ¯|˚kõ]çzö¥¯ÍÜêNgU™|ê_ã˚,˚˚&˚Õ4Ï¿¿§ªπçä˚NT|~AÑ{‰˜ÎkÑ~t~srÖs>W◊˜˜	¡Ÿ‹Õ™kF˚*ív¯ewû¯\¯o¯Gõ˚{´äöÄv|Çoy]=˚[%˜îÜòáúãíúòî¨çõ˚W{üäïÜó§s˜˚ø£NéÇòeîãíãèíù∑˜˜‘¶Œíî©ç˚*˚m¯Àwô¯`¯n¯Iô˚}ØàóÑzÑéîqB<˚q˚˜êÇûãíãñúííΩëô˚a}®ÜóÑîw˜˚ä¶PÆJ|tpG{rt|z||wuùloxzpk™r¥“µº˜*ƒ˜/¯-ñ©ôò°é˚—ãû˘û˜Ò˜Ãü8é~ó÷¯O÷òóﬁéü˚∫wﬁàò@¸O@~8àw˚*ã◊¯§‘˜Â·¯n˜~êmdÜpPã˚Ñ˜=˜D‚Ê≥⁄ã⁄Ì:Ÿ&˚HK˚lüÜØÍ≤Ø”ã›ƒP6?\*95˚F˚P~¯Ä˜—˜˜I∑™r§mlrrlm§r™©§§©dãû¯Ì∂ü°˜gÒ˜|v¯„¯ÅÑ˜>¸ƒÑ˚>§˜°†õ˜¡¸í@~8àw˜∫ü8é~ó÷¯í¡˜†{˚°”ãû˜º∑˜±ûıÒ˜√Ò˘PüAè~ò”¯Q”òò’èü˚®w’áò~C˚W˚√˜W”òò’èü˚®w’áò~C¸QC~~Aáw˜®üAè~ò”˜b˜√˚bC~~Aáw˚bã©¯©¶¯¯6˜yèv*|~/ã˚˜¢¯*ö˚Ôà˚ú’ïôö»˜˚ù¸*|¯˚*†v¯Wwú¯b¯sõhçyòn∑˚˜Xﬂ˜û¶ßõ≠åö˚3}¨áíá}~uU?~üèÖs≥x™Ñöãìãõïë´çô˚b}µäêá∞SÍ˚%˚˚9pd}Ålä{˜%õnÄêóìêóô°€˜‹˚õsãäãÄ{ÄÑrá{¸†v¯bwÃ˜r˚Uﬂo ˜œ˘ú}ôz|}Ñ||˚'˚)≥˜.Ïûóîôãú˚≥˝–˜êõKèÅñ”˜˜ÜèXyWxXx|é©åãì¶î{_˚{CÅGà{-~Ø¯¯¥—·˜~Ô¯~˜<€\ƒ˚’Q≠"º‹¿µ≤∆Â–L˚ ¶§u˜hvsÖÇÅzÑ|éê}üOwëq"?D)9≠a˜C˜>¨hNGZ\C0M¿˜Wu©˚h††çñóùØ´jÁ˜
„ÿÛ˚*Ç¶¯4ß…Ô®‰zÔÓÔw‰ﬁ,˜—¯“ßu°oouuoo°ußß°°ß˚[ßu°oouuoo°ußß°°ß˚]¸““¯i˜~˜0È˚˚0+˚˚Á'˜˜ÍÛ˜2h˚^FA8O˜˜*ÁºÃ–ﬂ«*˚˚—⁄˜ ˜o¯ﬁøh≤\jrskk¢wØîñèãìîåëÜäÅâhohVgïwŒ≠∏»≈˚—˚1v˘Íwª‡˜ƒ˚6˚·Z˜˜l˜[∂Ò˜ÓÇõ˚@˚@˚ã˚L˚µ#Î%≤aßt≤t˚—˚1v˘Íw˜\‡˜±˜ä˜aÛ+Òdµo¢d¢{˜5º˚˚l˚[`%˚(î{˜@˜÷˜ã˜L˚*†v¯)¬åw⁄‹:ﬂ<˜›Bﬂﬁ˜ﬁ˘mf{~r~tëì{tóvñsëuãUhiI}®™ìùößïòàÑô°ÄØy¢Ö¢ã¡©©÷†¸1˝“¯xõ]}õº˜yË^ƒB[p|ID€™ÑçYxà@tyéôëåì¶ì{[˚ãS}z\â{˜göYê{ò≠˜≠ ª√õî¨ª£kJ˚eN}xZà{˚ôív˘&û˜CÒ¯˘ü˚¥w⁄âô}C¸d\Äwq|Üë£Ñ≤|õqqutp_≤n∆˜ »”˜¯”ôô⁄çúã∞fû˜»≥c≤˜ó±xû˜Ò˜Ü;˜¶Ä¯Â˜D≈oΩ\ßröyíZôçg Ë°≤∂⁄˜.«˚<˚¨wﬁàòA¸QA~8àw˜‚¶Ä˜%Ï“Ùß ˚˜Ã<Yb)äõ -ä˜yßèç√˜»]0¶Ä†˚»*O]˚O|ì¨˜ç˜Vå–d˚”}Ø¯˛Ø≠˜¯?˜˘C˜ﬁ˜_˚˜#˚S˚T˚˚#˚_˚]˜˚#˜T˜S˜˜#˜]˚å˚T:˚	˚˚:˜	˜T˜R›˜˜˜ﬁ˚˚Rúãû˜¡§˜ÆØxûÒÒ˜}˜‹˘'üdçvóp¨˚b˜ë˜¢ƒ¿Ë˜/ ˚7˚ßw‘Üó~D¸D4ÖÑ=Éw˜®ü=íó“˜X√é˜Ç˚…N¯"Kc˚=ä˜äÏ®óíΩ˜≈]1”ãû˜[¥¯4wö˘G¸5˜r˜X˜i˜œ˘ú}ôz|}Ñ||˚'˚)≥˜.Ïûóîôãú¸ì˝˘Vü^ç}òl”˚ç¯Ãw˚d¸O˚!}xYáw˜Zü\äuô™ïéïëõπ˜
˜ö¥*ïtîlãpzÉWwÜ˜ó˚{˜˜ß”ãû˜[¥¯4wö˘G˘Vü^ç}òl”˚ç¯Ãw˚d¸O˚!}xYáw˜Zü\äuô™ïéïëõπ˜
˜ö¥*ïtîlãpzÉWwÜ˜ó˚{˜˜ßú}∑¯Ov˜M≤ß˜˘˜yú=AOp5ã˚+,˜˜K˜SÂ˜	˜(ˆ“N˚∞°Ç˜tvÉu|wåÅå{éxíbôYìaã˚Zã˚!˚#ã˚]ã˚f˜˚˜_ã˜ã˜ øæ◊”ïvñû˘û˜ ∏¯1∑x˘T˘ü˚~wÂÑëk4˚„â¸¯u˚?w∂åñÑµ[¸M%~y8Éw˜ü>éz£¯ç∏¯J¸πú¯§Ôöü⁄ë˚—ãû˘ûÈ˜r˚^Òå˜i ˜œ˘ú}ôz|}Ñ||˚'˚)≥˜.Ïûóîôãú˚–˝–˜Ãü8é~ó÷¯O÷òóﬁéü˚∫wﬁàò@¸O@~8àw”˚Fû˜Gw˘Ø≠˜¯?˜˘P˚Eù˚å=∂5˜ ˜2•Ú˜ã˜Eã˜_˚˜#˚Sã˚Tã˚˚#ã˚_ã˚¡˚‚SÆu©}•ÖπT=Õ˜_˜,íåãå≤˚¯ê˚T:˚	˚˚:˜	˜T˜R›˜˜˜ﬁ˚˚R”}∑¯˙ûÚÚ˜¸∂˘S˘ü˚{w÷âûr(˚¢=Å`slakTtJO\ùÆnnÆÇ∞€˜‘‘ññ⁄èü˚Æy⁄ÉïÅB˚À˚@›6˜:˜HŸ›˜P˜ôõ†Ÿèdã±¯ﬂ±î¯ﬁ¯Á˜Dt˚hjq%˚ñ¯C¯ˆö¸°x˚>§Úü∞®˜˜q¸H¸ˆ|¯∆-ãû˜»µb¥˜ì≤xûÓ˜î¢¥¢œ¯µ¯úà˜#¸¶w’áò~C¸QC~~Aáw˜´ü@é{ö“˜p˜&âﬂäñÅö7¢˜|t6|Å8˚&˜q∑®êêß˜˜û~0ù˜Éãû˘ûˆ∑¯ú˘ÔüFçyù–¯Q”ôô‘éü˚[˚o¸é˚{¯é˚Zw›Üò~D¸+&|x;Ñw˜}ü@éx•Ì¯$ç˜é¸∑ô˜ê¯Œç¸V9Ä~<Üw”}Ø¯˛Ø≠˜˜"˜r ˜˜X˜i˜œ˘ú}ôz|}Ñ||˚'˚)≥˜.Ïûóîôãú¸ì˝Ë˘C˜ﬁ˜_˚˜#˚S˚T˚˚#˚_˚]˜˚#˜T˜S˜˜#˜]˚å˚T:˚	˚˚:˜	˜T˜R›˜˜˜ﬁ˚˚R”ïv˘#ûõ˘;‡˘K˘ü˚`‡x∆ÜôÇm}Ñqm˚&¸˚,˜ÊmÕÅ©ãô§ñê èû˚ù‡wΩàú{±6˜ã¸∫ö˜p¯∆®’õõ∫ç”}≥˜…û˜Æ≥´˜¯Î˘W˜„û˚íxŸáïÅ@˚4iOq?˚3'˜
˜O˜KÏ˜˜%Ù–U˚µ£É˜fuuÑ{ÄsÖÄçéÄ°Ejë\˚[˚"˚&˚b˚|˜A!˜K˜˜¬ù˜\≈ôö√é”ãûx∞¯·∞xûÚÒ¯˜ú˘?˜‚˜b˚)˜˚é˚†w’áò~C¸QC~~Aáw˜Ø˜Ç˜&˜˜cl˚Ö˚U#)˚a\~î´¯ê≠îë¡˜Q˜	˚˚L˚*~∞¯‚‡Ÿ˜˘—¯J˘?ÇëyuÉáwã˚e˚˚Ääâäàãâáçâëä˜É˜5Y˚.&O?;uÑé´^°l}êpr}~tb∑u›˜5˜ Ú˜.˜@˚ƒ˚)¶µ‡˜Xúéåíé˚*†v˜;À¯Qw˜∑⁄>ÿË¯k˜;À&¯Q_˚Œ¸QK˜≠˚;ÿ˜;<À˚Ñ˜Ç˜Èç˚*}Ø¯Á∆˜—⁄g“–¯C˜lÍkπ+∑‡œπ§∞≈⁄K¬/,MX˚döá≥÷∏´ ãÃ∏^L^r_cnpwvÅWyû¡¶Üz™–ªp®XO8QICqvì†h£cÇéys}~ug∑v÷˜1˜Î˜¸Ä˜˜ç˜‹˜˜T¯)©r§mlrrml§r™©§§™˚˝™r§mlrrlm§r™©§§©˜£~≤˜
≠i∑˜©∑˜™˜ﬂ˜”¯≥ﬂ˘º¯˜<˚!˜˚N˚_˚6˚0˚V˚S˜7˚)˜c—∂ñ∏Ô©<h\Mã˚D˚˜˜C˜O˜˜˜:˜,˜˚˚$#M,Gqö™êåíåêÃ˜íGÄew¥{ñhã&,˚˚G±[¡≥∏ß∂¨ç[ö®tºÎ·˜˜˚Ä°[tBmYøpzqytgs¨æÍ–ÌŒ¶õud-ãû˜°≥˜Ω±xûÓÚ$Ò˜{˜⁄¯±¯w˜$—˚3˚öw’ÉìÇD¸FCäp9âw˜¨ü<å|ö’˜Hä§¢äû⁄≈ñ°≤»≠Æ«œ˚â!S\˚ÊzÅãçt˜ôßíë≠˜ÕY-˚*}ß¯∫˜Çö≠Á˜ë‰¯h˜m˜Bﬂ˚[wÑeL™˜1ÓÍ˜;´áö˚vá˚M˚;˚˚D‰˚˜˜·Í˜2j˚ cME4SÈ˜'≤ê≠îô°ò∑ù¥ÂæC˚¸õv£v˜Û˜€˜ ˚˜h˜T¯)©r§lmrrml§r©™§§™∞ß¸øh≤\jrskl¢wØpïîéãîïêáÅäâiogVgïxŒ≠∏»ƒ¸ív˘FwÇ˜∫˜±˘8I˚x˝FŒ˚*ôv¯Ë‘ü¯@¯T˘ö¸|_`%úÉ≤Ã¢õ¡ã˜m˚Z¸ËÃ˚*âw˜ó∂¯ß©Á˜ÄÔ+ÎÙ¯^¯!˜5/˜
˚˚4'˚ ˚
‘:ˆ¿ªù±π¯åàm˚%˚˚>qçw˜Öõ˜3˜<ã˜Ù+bváÇÅuod}j>\’˜˜± œ‰∏4˚;˚*Åƒ¯(w—ﬂ°˜rIﬂ=Ÿﬁ˜œ˘ú}ôz|}Ñ||˚'˚)≥˜.Ïûóîôãú¸"˝‰¯rØôYäñ∫˜Ï˚2{ËÀáïÇY˚ÅràÄÉÅuy^wlcjÆµ˜€˚%{ªàò~[˚è;∫Y◊Ø±õ¶¶‰∑∂9çàŸßîéæô5†v˜pŒHÕ˜çÕ–¯©˜pŒ˚n˜pI∞˚q˚oI˜o˚pÕ˜p˚*†v›ﬂ¯çõ`çi°dº˚.˜V®¶ÔËΩÆÃâô˚_}ìêäãè¢äîáå~åÅÉÉ{|˚˚âç¯3ÜéOxzÜ>w{åòïãíØîZ¸uUââBÄ{˜~õMç~î¥˜Iç˜˚LûrçáãÖÉÇÖy{˜Kìvò™˜óÆö´˜g§œw»◊˜r§Ã÷˜q•¿˘ó˜ö—f≥H˚˚ ˚˚;ªW’ÛÎ˜˜˚¯2eYYbyDd{í†oür{ëo˚ ˚	˚BæQÕıÔ˜˜ôâñáûÉ£óâ£∑ßí†∞çâø¿˚˝∫¿¯Ö˜£˚:˚<du•∑œÀ˜?‚≤™f^¸˜º˚:˚<cu£∏»∞ÊπΩ£°°òúëçäÑíïÅöÑ®Éëéwã}˚é†v¯≠˜n≠ƒ≠˜n≠˜Î¯©⁄KÀ<<KK<<ÀK⁄⁄ÀÀ⁄iOZZOOZº««ºº««ºZO˜∫ñv˘"ûê˙1˙6˘ü˚Zw¬ÜôÇl|ÑkÇs˚˚Ë˚˜Èp–ãäãó§°ï¬ü˚üw áèá≠:≠9 ˚Ø˚%¯É†àïãò°óë¿êü˚àw…Çéá“˚SÃ˚CçÜË˚°ö˜.¯;ëyë|éÇë|°U™;±*ú[™4ôŸ˜Éñ™Ã˜H¶‘ö≥ñ©öµõóªë”ãû˘û˜Ò‡˘eüXzñÎ2˚|˜é˜Q˜Q««£óŒêü˚òw«áíàtrxs4:tu∫∂˚@˚0˜W‡ﬁñóŸëû˚¨xŸÖñ8¸;8Ä=Öx˜¨û=ëÄóﬁ˜D•°ı!ÿ>¿Fãt‡yÇàOâw”ív°v¯dw†˘4p˘I¯Gõ˚{™àòÅy~áu~l0˚r<˜kt…çÑãò£ôì∂èõ˚^{µäôv≠%/˚\k‚H˜CãÜõäìíüòî¨çõ˚G{¢äîÄüX˜˚Èkòëíëëî©ô˜˜ÉÂ˚∞^úãåíìååªû˜˜Óúµêíûêu°¯Wñ˜\öíã˜öî¸}é¶
ﬂ
_˜é˘endstream
endobj
10 0 obj
<<
/XHeight 677
/Ascent 684
/FontFile3 9 0 R
/StemV 84
/StemH 0
/ItalicAngle 0
/CapHeight 662
/FontName/LWLOVH+Times-Roman
/Type/FontDescriptor
/Descent -215
/Flags 34
/FontBBox[-168 -218 1000 899]
>>
endobj
11 0 obj
<<
/Name/F0
/FontDescriptor 10 0 R
/Type/Font
/BaseFont/LWLOVH+Times-Roman
/Widths[250 0 0 0 0 833 0 0 333 333 0 564 250 333 250 278 500 500 500 500 500 500 500 500 500 500 278 278 0 0 0 0 921 722 667 667 722 611 556 722 722 333 389 722 611 889 722 722 556 722 667 556 611 722 722 944 0 0 611 0 0 0 0 0 0 444 500 444 500 444 333 500 500 278 278 500 278 778 500 500 500 500 333 389 278 500 500 722 500 500 444 0 0 0 0 0 0 0 0 0 0 0 0 444 0 0 0 0 0 0 444 0 0 0 278 0 0 0 500 500 0 0 500 0 500 0 0 0 0 400 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 333 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 722 0 0 333 0 0 0 722]
/LastChar 238
/FirstChar 32
/Subtype/Type1
/Encoding 8 0 R
>>
endobj
12 0 obj
<<
/Differences[32/space 58/colon 75/K 80/P 82/R/S 97/a/b/c/d/e 108/l/m/n/o 114/r/s 117/u/v/w 121/y]
/BaseEncoding/MacRomanEncoding
/Type/Encoding
>>
endobj
13 0 obj
<<
/Length1 2977
/Length 2977
/Subtype/Type1C
>>
stream
  YFBNOF+Souvenir-DemiItalic   J¯ ¯¯¯¯Å)¡˚˚™˙o
 ãã
 ãã   ˝   ˘  (ö  í Nfr}ITC Souvenir is a registered trademark of International Typeface Corporation.ITC Souvenir Demi ItalicITC SouvenirDemi Italic    3 F T V N O 1 B M C S  D W  4 Z , X P E    ≤$ó6î(†’RÆØv∑P›Ø	V	©
:˚ ˜ã≥˘À√˜∂˜¨˜Y˜‰˜»˜ú•V√*ãCUSüãbyóÑöà˜l¢Øç´ôÑíÄëoúàûÑ™vÊ}ª[ﬁ†Ï®ÿ˜˜/˚:Ç˚˚ŒqdàiñÉîÖõîáv=¸kNèÉ\iÉÇÉ}oßãü˜M£¨å´ôÅëÇí|ñÅëû”¯E‡öà¡˜ Àœv?PhVXpSlC~LÑE|‹˜˜œ’˜?˜j˜'˜â˜JÔò˜ô≠˜#±p©lù°fXîa48nQINW\=9˚˜I˜Õ‘†¨√üó¬Ø®ö}ñ|}w}ÉÄo]aqS@_¥÷âåœÃï”ı”©®yj9˚)iKá˚|Œ¯Ã˜˜8—˜A˜¶|«≈ô¨Ω∑ß≠∫¡˜'˚áp‡≥≥ù≠ÎX-ã›®•ü™Æo§põ£cZì\SS~l\cqm\[˚&˜~§8ZZxacqï≥¨ÅÅ®bjpqi`≥lÆ{v∂æÉª©|Ó¯≥˜/˜C˜˜VÜnÑnm?–^—Ëœ‘⁄∞äzÜJãsè]¨ãòîêèñøüüì¿üöóíëëíï¨Jw¿¢î∏è¶≠˜Jçïë•ãî†qÜ~F}véÄÅÑVà{<Z˚y(ãnãxüã©ãùí©éûõ‚í≤ù”Æ¢Ñ´oh@k}iyÑm~smøù[}átà}˜ﬁ|≥¯Í˜.˜+˜7˜,˜5˜5˙7˜∞ë≠ê¢®÷K∑E/H:>héúéõú–P≤J)J4<dê™ë´´¢âªjnKn}r{Çk|ulΩüYi~IÑhi˚Iã~íÖîá˜îåëåèçïëèòê¶òÃñ»ô…¶√õÆ≠Ã∏ã´ãñoãnãh|AÑfp˚âÉáwÉ}íÖïá˜ïìëïé¢ø˜kπõµÁ≈ßópsuÅbápÉai˚+kuóv£™’•ñ®ûìΩö¶¨Lv∫©|≥¯È˜(˜4˜?˜8¯M˜áwÇawsìrßÆ †ò´ûìæú•ÆMrº¥˜{ã›E∫Cã)KC<_í¶ëß®§ÖµjqCjr{Ñh~ue¿®OsÉ]Üsb˚aà}äwùã˜üè°§êú‰ô”∏˜OÍã≠öpkwÖkáv—ã≥˘Ã≈˜∏˜ï˜W˜ﬂ˜ØÌÓô≤‰Ïµ„€˜–Y¿M°ûVCãS˚¥slÜm~ïÑîÑúîáu>¸játÜayzÑÑ}ÇÉÖÄÉÇÑã|ãp´äüã˜U†•î§ôÇíÄí{ñÇìû‘¯uè£ë¢íïõ£¨ê•ã◊ã»lã9ãKYQVjZnRRáÅ|‡˜“’˜7˜b˜¯:ÆqòsßßÀ©ò¶úí¨ñ£±Ml√«±˜Põ ®íxõ|k[eusµq\ù[˚5˚˚,˚3#«2˜ﬂ ƒ‘∞˚^X~≈¥∆°œ®Ω©ù±µ≤∂úhdSx?sXgyhT]˚∂|≥˘H≥Ù®wís£¨⁄©ò´üì≤ó¶¨Po»Ù¯·ãùîzãi˚3_bp∑ìãfÅ|—˜ÈË˜x≥˜X˜H˜˜?ÈºâÅàÄÅwô~û´º±†°b©øyΩ›€Æ∆√Ωø±‹÷˜HÊ˚	IRjXd∆˜–ã§|ñsã};vÅkuÑjÄom≥ò`˜p˚t…ôQY@X˚2-Vwµª∫ûÿ°∂Æù≤º∑˚Rã≥˜›˜˜3˜1˜wµÜû±ìøïπ˜òÀ©Ñ[ºªûÀ≤≤x•b3X4Coê™í´™§Ü≥j˚a|Ñh|ãuyõÖôÑ¢Åå}tW˚ƒãq®êùã˚|›˜Ò‘÷˜?˜ËŒHp√«¿ö ß∑Æ°¨±∑◊R)Ë≠¨£∞™v§sú•fWñ_˚7˚+˚˚;˚Ò@˜	»«ú´ø¢öΩ±™õ~ñ|m\=ã,E|‰¯≥˜-˜DÒ˜0˜"˜°x*Üwàvãu3Ôg’‰ﬂ≈”ºπÃ©Ê€√{›FcledE—ôãM8H˚+gv¢∞∞öÀí±ïΩí±î≥ã≤®ÖüjlJpmvÇc~nlΩ†\ÄâÄäÅ˚ﬁ|˜5˜˜5⁄˜R˚%˜R†˜7|ºƒ≤¿πc¢aVTdRa∫t∞P∑˜©º≈≤¿πc¢aVTcSaπt∞©|⁄¯˙–˜˜R˜L˜R˜Û|˜3˜OÍ˜F˜l¸
Uã˜.ßù©°ú†¶Øì¨˜c4˚8€öôîôíîûèÀ°òãñÇïÅónó~êN¶DöHã?ã@wMaN`bLã?ã˚˜c˜i¬z⁄wãEãgsiowktbÑdãBM¶”v∞ÅÄ≥\^of_J√`¡sm…À–1˚W˜ŒÓ¯≥˜˜6˜+˜ ˜º¯S•Çõnw4rÖvzÖkÅtyôáöÖ£ÉãÄtâ/ãRã<°XX†∑i√®ß§†§au+-_u}¢lklwj`∂z∞˜˜˜+ﬂ≈ÀÁ‘˜'˜∏{¿Tdmhfpó|úxôzèÉuVC˚@LGá˜&∏˜ã≥˘ ≥¬˜≥˜/˜∞˜˜6~EèãXgÅÑÑÉããq¢àüã˜O£¨é´òÅíÅë}ñÄëû™˜PÊ¡¥H›˚7ãw|ÇàÄÑ~ÇÉ{g∂ê£˜0•Æé≠Æjyy«y»iœm√6˜˜s˜]óîìéöíüîûñ§•rèu˚"tqÑpzïÑòÉíÜêàÅ|zzÄÅ[`˚<˚$Fe™˜Pï≈âôπ©óîñíãöã¶révã˚LsjÖm~ñÑîÑöÅïÖx˜R|≥¯<≥˜+˜E¯˜!˜˜{ÑhQihóo¶ux£±|™ÔÃÁ·´áxàxw=”a—Í ∆Ÿ∑±À®ﬂ÷ºÄÍJbsbfDÃòãMKY˚';iz©´¢˜O°˜	å≥hÜyã]iuëbÑ~6ÄFp<}ce1WãlãÇ®ã§ã•ì≥è§ûËë´ó¡´´~ùklJn~myÉgrmªú]Å|“˜˛“ÿ˜?˜Ö˜?˜‰|€ﬂ¶ø…≈Ω≥’Ÿ˜(˚÷˚8:pTMRVd?<˚#˜D˜ê“Et«»„≤˜-˜Œ§RP4e˚3˚©|·˜Ï’˜x≥’˜?˜k˜¯z¯9ªndüQ˚2˚˚5˚+"Ÿ4Û——„ØÑ+ãtêd™ã§…§î†ùìºú§¥Gj…Î¯‡ã†}îwãg˚/n]|öÖñÖúÅêÇw˚Z¸µvtöúÄ{¢á®•¡°–©∏™†¨Æ¥¿ö_^V{Fs[fxi[\|ö¯uì˜á§˜Ë˘endstream
endobj
14 0 obj
<<
/XHeight 757
/Ascent 732
/FontFile3 13 0 R
/StemV 190
/StemH 0
/ItalicAngle -10
/CapHeight 732
/FontName/YFBNOF+Souvenir-DemiItalic
/Type/FontDescriptor
/Descent -15
/Flags 262242
/FontBBox[-123 -278 1296 987]
>>
endobj
15 0 obj
<<
/Name/F1
/FontDescriptor 14 0 R
/Type/Font
/BaseFont/YFBNOF+Souvenir-DemiItalic
/Widths[340 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 320 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 780 0 0 0 0 720 0 780 680 0 0 0 0 0 0 0 0 0 0 0 0 0 640 640 540 680 580 0 0 0 0 0 0 360 980 680 640 0 0 460 520 0 680 580 840 0 560]
/LastChar 121
/FirstChar 32
/Subtype/Type1
/Encoding 12 0 R
>>
endobj
16 0 obj
<<
/Differences[32/space 58/colon 65/A/B/C/D/E 73/I 76/L/M/N/O/P 82/R/S/T/U 97/a/b/c/d/e/f/g 105/i/j 108/l/m/n/o/p 114/r/s/t 118/v 146/iacute 151/oacute 238/Oacute]
/BaseEncoding/MacRomanEncoding
/Type/Encoding
>>
endobj
17 0 obj
<<
/Length1 5624
/Length 5624
/Subtype/Type1C
>>
stream
  YZXDAM+Souvenir-Demi   G¯ ¯¯¯¯)¡˚?˚Øa˙É
 ãã
 ãã   Ê   ‚  3ö  È N_koITC Souvenir is a registered trademark of International Typeface Corporation.ITC Souvenir DemiITC SouvenirDemi  %  0 C K F U J W P  % T D S Q ÿ O  E M B $ N * / 5 3 6 ª . " & 4 1 - # H G ” '   b ›M¡°#s©îÌxßeflÒ	w
í
¯¥>ˆê-ˇòIÌÄ¯ï.ºd˚ ˜f|◊¯ˆ◊´˜W¯(˜W¯;|˜n˜M˜3˜t˜w˚H˜,˚p˚n˚D˚1˚r!∞+◊BF‘ÙdÔè◊˚1`˜N˜ÕîÀ©∆À¨¡∫÷˜3∑˚H˚˚_˚B˚4m|–˜˚◊˜x≥≈˜7˜W˜A˜q˘'©ëœ\lRxÅmxÜaÖp{òÜóÑúÅìÜèvéuãlãu˚ÙIëN≈ak∏Œ~¬˜6˜Ë˜@˜5Ô˚!V\xjbé˚)®å©ú§§úßõ™‹ú˚OHx 59ÜÍ»˚Ú˚W˜¯ò≥ƒ˜3‰˜7˜1¯∂∏¬¶ø¡Z•Z[ZlVZæq∑G¸ˆÑéi~w±ãbluslSÿz∂«ƒ®æ´©πãƒ¿˜Ú©ëœ\lRxÅmxÜaÖp{òÜóÑúÅìÜèvéuãlãu1|€˜ˆ—†˜A˜E˜0˜_˜@…ïÃë«û»ü◊µã’ãÙ˚¥2ã˚0ã˚%'ã˚<ã˚'˜2˜ã…ãøñø™¶ö¡µãØãö|ó}ãwÑÅ}gcbsUJY∑ }ÇŒ—Ü±˜ﬂ≥üpe8˚pIÜ˚¢ãÿ˜Ÿ⁄⁄˜7˜Ü¯&≈ß´èÆ≤kåmP˜µáë]cÉ~fÑárÄ^~v{ssàpáuáyÖãqãd™ã®ãü˚ŸG†Ç ˜•¥çØ∂eámWÜ§∏˚Úã≥¯-≥ƒ˜3Ÿ˜7˜#¯∂∏¬¶ø¡Z•Z[ZlVZæq∑J¸7~åpÜ~áÑÉÜÑÜÅÖÉÑã~ãtùÉüã˜=üùì¢òÉíÅëÑêÉêáíÜòå¶ãò˜ú©ëœ\lRxÅmxÜaÖp{òÜóÑúÅìÜèvéuãlãu˚|≥¯4≥à˜ë˜˜A˜–˜fƒE˜2 ≠¥à¨´aât˚thåk{ñÑñÉöçÄêxÆ˚∞˚ ’˚§fûÉ∑ã¢ã†éõúùû†≥ó£≤÷´⁄°‹ñµîØäã¢£ììëîãòã´aÖvãTwhélhπìã]hr9|hm|–˜ˇ”•˜@˜u˜@˜…|˜%˜!Ì˜1˜*˚Ó˚!?BvXQX]iIEB´Gƒ\_¡“y–å–+{˜÷’¢ÒÊ‰°(C=~˚'|˜5˜&˜4’˜R˜?|∏ª©ºΩ[´]\ZnWXænπ˜«∏ª©ºΩ[´]\ZnWXænπ˜>ã“¯‚“÷˜J˜⁄˜W“˘pupÑpyñÖòÉñÖ°Äátãv¸rvètuÄÄÖ~ÉÄÖãyp¶Ñ°˜◊ÙÒ§◊◊—“™ÔÓ˜bÔ1—œ5+ñ"$˚1 ã¢“˜@ﬁ˚#˚2˚/9˚˚;?ä¶—˚*|“¯œ±˜8Î˜>˜ß˜Àoí^ñØ≥µõ≠Ïá5ã∏®å¶°°ã´vò•dBó]#˚]˚˚H˜òŸã%`X{iYv¢Ækõ}Çòtsyusb∏m≠|xµ∂Ñ∫¿ƒó¶∏∫©¨ª√ËEß?ü˚|‡˜Ó‘¢˜A˜X˜~äÀåü˜
ﬁ’á0‘™¶†¨›˚"ßL˚+˚&˚1˚-˜.˜$≈ƒ†´ª°õ≠®´õözz~}ÄÄmmavaá1f‡⁄˚fã≥¯-≥Â˜7˜ë˜jÆçµú™ùîõû††ü~•Æù±™∂k™`QZTZs¨ÜÑ“^uMvÉvxÉmryóÉöÑ†ÅîÜëuëwãvãô˚K}ãoÜ~áÇÅÜÉá~ÑÄÑã{ãk©ã£ã˜1£©ã´õÄí~íÉèÅêáîÜòãßãôÅ˚L≥˜ﬂ˜„‡⁄˜7˜]˜@˜Ü˜©´å∞¢•†ù£ñßﬂ¢"IaÉZrhsypzm{|é|}É~]—~≠˜!Ú˜˜"˜2˜˚%OYr\_•áÑπil˚eg{ñÑïá≠záyh¸}ãoÜ~áÇÅÜÉá~ÑÄÑã{ãk©ã£ã˜1£©ã´õÄí~íÉèÅêáîÜòãßãôm|–˜ˇ”¡˜N•˜@Ü˜të˜@˜(˜ù˘(öñúï†™lâvâ^däâÉxjW0ÜÉÅ}ÄñÉóôõôìñ˚ï¸…‘˜…|˜%˜!Ì˜1˜*˚Ó˚!?BvXQX]iIEB´Gƒ\_¡“y–å–+{˜÷’¢ÒÊ‰°(C=~˚'mã≥¯-≥–˜7˜:˜7¯≈˜∑ΩÑ√g≤±gTöXJUtZc•áÑπil˚eg{ñÑïá≠záyh˚S~åpÜ~áÑÉÜÑÜÅÖÉÑã~ãtùÉüã˜=üùì¢òÉíÅëÑêÉêáíÜòå¶ãò˜/¶ã™ö£ßú¶ò¨”çMT˚5~åpÜ~áÑÉÜÑÜÅÖÉÑã~ãtùÉüã˜=üùì¢òÉíÅëÑêÉêáíÜòå¶ãòm|€˜Û‘˜x≥û˜A˜[˜7¯¯\°djñ^˚'˚ ˚˚'˚Î˚˜»øüƒ≠^éãzæÔ£©ã´úÄí}íÇèÉêÜïÖòåßãô¯û©ëœ\lRxÅmxÜaÖp{òÜóÑúÅìÜèvéuãlãu¸	qäu}tqzn{l3xÒ–“¢˜‰§§Äxõûuçrp˚Úã≥˘9≥‘˜7‘˜}ãoÜ~áÇÅÜÉá~ÑÄÑã{ãk©ã£ã˜1£©ã´õÄí~íÉèÅêáîÜòãßãô¯†©ëœ\lRxÅmxÜaÖp{òÜóÑúÅìÜèvéuãlãuE|›˜O ÙŒ§˜<˜5˜6¯ò˜ª—xæMØßZMîSZ˚2~Eh¨~® îÀã»À®^Oi˚˚Hh˚"$·WÈ»«†√≠^éãzæÔ£©ã´úÄí}íÇèÉêÜïÖòåßãô˚6˜	kcåkuhpyqvjbu≠±€”Æ“˜|„¯Ì‘´˜W˘¯∫wïól¶§úö£°à–ÖûÜö}ï}ìJ∑2°=ã˚mã˚X˚>ã˚tã˚r˜J˚&˜hã–ã‘ú∆Æ∞°Œæãªãû{õxãrãwq{{[]KmL@F™Õcj√y›Ã‘ö”µ»∆¥»Ø“∞≥~r´¨rórúg˜¢ã≥¯-≥œ˜7˜,˜7˜,˜78˘Ò˜∆ΩÖæeØ™jZö_GKtQd¡mV¶OLQq]c•áÑπil˚eg{ñÑïá≠záyh˚S~åpÜ~áÑÉÜÑÜÅÖÉÑã~ãtùÉüã˜=üùì¢òÉíÅëÑêÉêáíÜòå¶ãò˜*®ãÆù£°ú¢ó®ÕäF[˚/~åpÜ~áÑÉÜÑÜÅÖÉÑã~ãtùÉüã˜=üùì¢òÉíÅëÑêÉêáíÜòå¶ãò˜*®ãÆù£°ú¢ó®ÕäF[˚/~åpÜ~áÑÉÜÑÜÅÖÉÑã~ãtùÉüã˜=üùì¢òÉíÅëÑêÉêáíÜòå¶ãòã≥˘ ≥◊˜J◊˜vètuÄÄÖ~ÉÄÖãyp¶Ñ°˜R°¶í¶ùÄë~ìÄëuñè¢ã†¯r†á¢°ññëòìñëãù¶píu˚RupÑpyñÖòÉñÖ°Äátãv˜ã≥˘ ≥‡¯4‡¯Ó˜®˚˜QW‘CÙO ¶rÖäf˚qläjsûÜûÖª|Ñfå`¸OäâàÇÑy|á{ÖzÑÉÑãxãi∏é¢ã‚¢∏à≠ûÉízí{ë|èÑùàîâóäó¯7˜Õ¸Cõs≤Mùy{öôã°»éõ¬¯≥åóçóéîíùöèõëúíìíãûã≠^àtã4t^éixìÑúÑõÖöáíyéÇçå©ã≥¯˛’˜ä˜J˜ä˜vètuÄÄÖ~ÉÄÖãyp¶Ñ°˜R°¶í¶ùÄë~ìÄëuñè¢ã†¯qØàù∂˜ç8ãπ£ôö¢ñàñâïàùÑæ|óÇísäã¸îsåÑÇ|ÑXàyâÅàÄãÄãtô|£ãπãçﬁ˜ã∂ãàyãgÂã≥˜ùÿ˜´“◊˜J˜~˜W˜ó˜≈Óõ≤_ﬂ˚ãXo`éãmiØå£˜Xû¨ç¶ùÄè~ìnõÖö~©i„c·J—€∞” ãÈã f√SßZ§LçUã˚¯äupÑpyñÖòÉñÖ°Äátãv¸qvètuÄÄÖ~ÉÄÖãyp¶Ñ°˜S°¶í¶ùÄë~ìÄëuñè¢ã†ä¯T†ã©ööõö±è†⁄Õg4˚	˚ f-â˜|ÿ˘
≥»˜J˜Û‡˜á¯èµáë∞õôêïìãúã©lètã˚UupÑpyñÖòÉñÖ°Äátãv˚∂0î+—HR«Ôx”·Ú°—∆ƒœçÓﬂ˜ª®ïé£óôíóíù´iår4riäkyóÑôÑ£ïàn˚ UãDq[WoJqUMO§»mrºäÀ¡˜f|◊¯ˆ◊π˜N´˜W·˜tÈ˜W˜Ñ˜é(˜ù˘(öñúï†™lâvâ^däâÉxjW0ÜÉÅ}ÄñÉóôõôìñ¸˝√‘¯;|˜n˜M˜3˜t˜w˚H˜,˚p˚n˚D˚1˚r!∞+◊BF‘ÙdÔè◊˚1`˜N˜ÕîÀ©∆À¨¡∫÷˜3∑˚H˚˚_˚B˚4˜¢ã≥˘ ≥ﬁ‡¯z˜J¯c˜¬˚ ˜˚|≥Ü™[ã˚WqläjsûÜûÖ£Ññ~èzéÉãÇãá¸täâàÇÑy|á{ÖzÑÉÑãxãi∏é¢ã‚¢∏à≠ûÉízí{ë|èÑùàîâóäó¯=˜D¸0ùdòà∑ãæè†µù˜6¯&¸FvètuÄÄÖ~ÉÄÖãyp¶Ñ°˜R°¶í¶ùÄë~ìÄëuñè¢ã†¯w•çö¶ìûëüë§¢|òx˚N^áÄbzÂã≥˜Z›¯≥Ç˜,˜‘˜≠˜
§øÜ∞∞WÅã∑´ßŒïÆ˜¨ê{íu¨(ãzt`èãkk±ã¢˜=£¶ê®öÑíízïÜéÉûhÛ˚a¯tvºóSãfyâjyoXsYuYX˚W˚e˚g˚ÑyÑá{ÅÄÉÅÉã}ãd∏ê¶ã˜&˜”˜˜ûˆ˚éê{ïã‘¯‡“÷˜J˜ï˜¯˜+œÉhã≠≥Üƒ¶§ã∑hiñfãD˚+˜Nòïñöëíù∑å†©∑âÖ•ßÑõûuò{ñ}°ã•ãïüã¢ã†á≈~õôpâ{ã¸gupÑpyñÖòÉñÖ°Äátãv¸rvètuÄÄÖ~ÉÄÖãyp¶Ñ°¯}∏ìèµòî§ò≤¶ûyôyqtmy{\`dàO˚åíÚ©|⁄¯˘—º˜H˜å˜D˜˜¯nRôFü”Ãœ´ƒ˜8É˚"ã¡§óú£§ã¥Ñ£áôÄìíI≠:ùAãEãA}RaRadGãDãI≠R¡f∂nœyæÇØÑ«~´{´|ùoãh;6gF_\ó£fj°}§v´}†|õpãnãwpãoãO–UΩs∆pŒÄÃã‹ãÿûÃº»∏∞—ã◊ã≈p¡^∞d™Oû[ñ©ã≥˜Äÿ˜…—’˜J˜r˜W˜î˜®ÂèÌï‹≥€≤œ–ãÍã’cƒK¨P©HêKã˚…upÑpyñÖòÉñÖ°Äátãv¸rvètuÄÄÖ~ÉÄÖãyp¶Ñ°˜O¢∏à≠ûÉízí{ë|èÑùàîâóäó¯a†ä¢õööößçüﬁ»Z5˚
˚`+~Yã”˘ ≥ÿ˜Jÿ˜vètuÄÄÖ~ÉÄÖãyp¶Ñ°¯U∏ìèµòî§ò≤¶ûyôyqtmy{\`dàOfRé}ã∆¯k†á¢°ññëòìñëãù¶píu˚RupÑpyñÖòÉñÖ°ÄátãvÂã‘¯„œ÷˜J˜ù˜W¯^Ã ó≥¿º∞®¬…˜2Œ&ûœß‘≈‹ƒl∫Zß¶\TéW˚ˇupÑpyñÖòÉñÖ°Äátãv¸rvètuÄÄÖ~ÉÄÖãyp¶Ñ°˜N¯„úä§óòúõØå†…÷Ä<!˚X4y:˜*Ø»y¡UãH#0e1umãözzöç°†Y˚Wﬁ˜”˜€ °˜@˜K˜@˜ø¯}GC~`TS_qFE˚#˜;˜••éí§¨}¨wcK:Ä[tAí≠ëçèéêçèçéê¢dé{\LtR1˜VÑ Ï˜K¢˜–PÆPôÕ∂Æ ⁄øxøg≤•£å∞å≠µhäkT/ê5¸>Åı√√û˜’‘ú%SM~ 8˚∂ã≥¯ ÿ˜*˜Â˜7˜ë¯(´≠ØÜ∏∂`Ömn˜ìäªõì£nã©´¢•´ΩKùbDLlImqTãGåSxz}é|ÖÑàÅÇd§ã´ò˚°}ãoÜ~áÇÅÜÉá~ÑÄÑã{ãk©ã£ã˜1£©ã´õÄí~íÉèÅêáîÜòãßãô˚Úã≥¯-≥¡˜N¨˜t˚G˜7c0˜ù˘(öñúï†™lâvâ^däâÉxjW0ÜÉÅ}ÄñÉóôõôìñ*¸…»Ÿ˜~åmÑáÉÉáÉáÅÖÉÉã~ãtûÉüã˜9°£éßôÇíÅëmúë†™˜Ü¶ãº~£öÇÄêzd[ze{ÜjÅszôÜòÑúÇïàéwèuãlãt|ö¯uì˜á§˜Ë˘endstream
endobj
18 0 obj
<<
/XHeight 757
/Ascent 732
/FontFile3 17 0 R
/StemV 163
/StemH 0
/ItalicAngle 0
/CapHeight 732
/FontName/YZXDAM+Souvenir-Demi
/Type/FontDescriptor
/Descent -15
/Flags 262178
/FontBBox[-171 -283 1377 1007]
>>
endobj
19 0 obj
<<
/Name/F2
/FontDescriptor 18 0 R
/Type/Font
/BaseFont/YZXDAM+Souvenir-Demi
/Widths[340 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 340 0 0 0 0 0 0 740 740 760 820 660 0 0 0 340 0 0 600 920 760 860 680 0 740 680 680 760 0 0 0 0 0 0 0 0 0 0 0 580 620 520 620 560 360 600 0 300 300 0 300 920 620 620 640 0 440 500 380 0 540 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 300 0 0 0 0 620 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 860]
/LastChar 238
/FirstChar 32
/Subtype/Type1
/Encoding 16 0 R
>>
endobj
20 0 obj
<<
/Differences[32/space 40/parenleft/parenright 44/comma/hyphen/period/slash/zero/one/two/three/four/five/six/seven/eight 59/semicolon 65/A 67/C/D/E/F 72/H/I 76/L/M/N/O/P 82/R/S/T 86/V 97/a/b/c/d/e/f/g/h/i/j/k/l/m/n/o/p/q/r/s/t/u/v/w/x/y/z 135/aacute 142/eacute 146/iacute 150/ntilde/oacute 161/degree 168/registered/copyright 213/quoteright 231/Aacute]
/BaseEncoding/MacRomanEncoding
/Type/Encoding
>>
endobj
21 0 obj
<<
/Length1 9961
/Length 9961
/Subtype/Type1C
>>
stream
  TWGKIW+Souvenir-Light   G¯ ¯¯¯¯%º˚1˚aï˙_
 ãã
 ãã   „   ﬂ  nö  &⁄ N`lITC Souvenir is a registered trademark of International Typeface Corporation.ITC Souvenir LightITC Souvenir  D  % F T D S J C  M B P E V O Q U H N G Z   R ÿ  1  ◊ I W 4 "    L  	   
 » œ - ” [ Y / K $ 3 5 X •   )   ' . * 0 ™ ´ & 7 °  F   z Ìo’H JK™Lü'¬giŸ	\

2
m
¸íÆ;Ω™hË{≥7e/¥sŸ5ŒHÛÄ<ÒmÛ¢5Á÷*f$∏@ﬁ ö ˆ!d""˝#Ø$B$Ç$‹˚ÚÂãæ˘
æ‰Â¯?ÒÃ˘p{xâvzòàôÜòáûà|¸¿déÉe~áá{uûäú˜ó˜Â†⁄€—“ÆÈÓ˜bÚ)‘–.-è˚/˚.›í†ÊﬁÍ{N… N•-5˚Y˚˚˚W˚é°Ú˚*|ƒ¯º¶€˜°€˜˜Dœì“íÀ§«¢«µã”ãµp∞h°mûfíhã˚(ã˚	˚ã˚'ã˚Ù-˜ãøãºú∂®†ôµÆãßïÇìÅpi7ã˚;DΩ›|Ö∂˜ä≈Ò˜ª¥tV˚˚My9É˚é|ª¯$∫¥ ˜`—˜N˜∑fï^ö∏ΩΩ°∑‰£@ã®úáÆï°äóxñ°e`ï`acÇpjjqwda˚I˜ü‚˚TSo[stíïurñÖïyüÅñÄúzã}ãÄ{ã~ãm™o¢}Øu±ÄµãËãÁ«ãã¨yÆr†tübômì˚R|≈¯º®€˜Ì¯zôê~£ûö†ù•w°wò°kcñe˚$(˚
˚ ˚›#˜¡¿°Ø≥ôò§¶üñÑíÅ|Ç~ÅÉgm[x]*R·Â∫ó∆§≥∞°≤®∑ªûxh¶˚∂ã≥˜ˇÿÊ÷˜:˜∂ï™û´£ô®±©ü£vúùê¢ô∞y£dSQ=[w®áÄÏd}luÉÄÄÉ|Ä|~ôáîáûÇ£sc˚ÑkràÇàÇáÉÜÄtùäõˆúõç°óÉèÅêÇévè©¸.ã≥¯$≥ÿ˜‰÷˜¯¡≠£°Æ©s°mlrukm†r™‘¸¡ùöçüôÅèÄèÇéÄéÜîÉöé¨ãõ˜\∞é∞Ö∞ùàãßrÄyÜÄ|Öf{ÅÅÜáäáãÖãóáïâ∫ÅÉqé_˚gbÖ{nÉÄàÉÜ~wùâõ˚|∫¯!æ˜Å≥…÷˜®€…˜gUçIÆ_]Ø≈{ƒŒ–®Ω∏πøõÃŒ˜N˜˚KRk\d˜Œúå§sxZvÅyÇÜÄáÇîáíâûÑûáj÷˚≈π®≈µƒ∑Øigü†fñUa0a$!bdüÆtsÆäª¥¸Bã≥˘9≥’÷’˜zêbz~yÇÇÜÉÜãÄwïâú˜†ëçüóÉèÅêÄëÄêäéàóÜõå†ú¯Êúé¢sx[uÇyÉÜáÉïÜëâûÖõÅs˚*|√˜y∏˜	ª§€˜ç÷¯A˜∞«{æ[±´bQöWb`Éye|Ér{xzòÉöùóïîöû´ùì≤“ ]AêNéLãJÄUhWjj^L+ﬁ\‚”ƒ≠«±rgáy¥∑õ£ä¢ôÅèÄéÅéÅèÖîÉöå¨ãõ@˜$:`Öhinrn_~eqqïùwxúÑ°§Û˜¨ﬂ1|º¯!º™€˜Ê€˜≠¯t˚˚˚˚˚˜˚˜˜"˜˜ ˜#˜˚˜ ˚á¸R˚TÁÒÚøÔ˜˜∆0$ZYmdbl[sX˚|ƒ¯º˜Å≥ô€˜´÷¯	¯I¶`kõV˚!1˚˚˚€˚˜…øßº±^çzò ú†Ö®óÉèÇêëÅêÉìãõ˘úç¢sx[vÇyÇÜÄáÇîáíàùÖùáw¸ùrãxyqq_{f˚bÎÌÁæÚÙæ®ys∂˚|¬¯$≥ ÷˜á÷ ˜D\êY©dg¶πx∏Ã…∞π∂eòmö—úîçüòÅèÄèÅéÅéÖîÉöå¨ãõ˜ª°è¥kzjÉÑ|ÄÜÜ~Åîáíá©zÜnl˚;gêupnjmWw_ijö™{~§å´ß˜í£á™k{D{xÄïÖìáóÑìáè~ízänãy1ã≥¯¬⁄÷˜ñ÷¯{˜±∫à»i∞ØkXô\;XoP\£áá i{tvÇÅÉ|Å|Äôáîà≠Äâpl˚ñtràÉàÅáÉÜÄm¢íú˜ôóîôòÇèÄèÇéuè†˜l≤çß©ß§ß≥úµË¢][˚óusáÉàÅáÑÜÄmüíù˜òóîôóÉèÅêÉèté†E˚Xæ˜æ¯≈Í÷˜æ€˜>˜†∫îÆØ¨•®∞ò≥˜±+-\ÄWpdjt_rariëñtéÜÇèÑÄÑ~ÅfÂ|§Ãœ®Ω∂∂ºô À…{«b∫∏cS•OB\iW]´ÉÑ¡auJlq|ùãïâ∏Öà`h¸*jàfnÇÜÑávïãù˜úìçûòÇèÅèÇèÅéÜîÉöå¨ãõãº¯ª‚÷˜6¯=‹û£ä•ßrÜu>˜'ôã£vqäcyâârÄTÇuÅrwãwã|ãyàã{ãh©ëΩã¸oçw¨˜öõìú¨_ÇwQá¶Ω˚˚`√˜>¡˜˘∫°€˜™€¯7¯9°ΩÉ¨•påqZDåëK˚-+˚˚‹,˜••êî§µx∏uU;$ÇOi!êºîçìãììáíÇoq^qE˜#ÇªÈ˜8¢˜ÀTµTü√∑¨Ã”Œq≈]π˚/˚Ì.eÁ€ﬂµÌÓ≤05-b5!˜Rã≥¯¬⁄÷˜}÷˜}÷˘ñ˜¥ªÜ¬k∞Æm^ú^JMhVf√i_´HHSiUd°àÖÕlyxyÅ~ÇÉw~}Äôàîà∞Äádk˚ävxáÜÇáÑáÄwòà§Úúöç†òÇèÅèêwå°˜à”€∞¿‰ñBD˚eutâÇÜÇÜÑáÄvñâ°˜°ëç†óÉèÅêzìä†˜à”€∞ƒÆ´{kõòqãko˚ouxäÖÅÜÑáÄvóâ¢˜ üíç†óÉèÅêÄëÄêÑçãöã≥¯ª˜ÄŒÌ÷˜A¯=»ù¢ä£®wátP˜®ÜÈ∏ññÇÖìáëéáìüõùü´lümKcRSzzRçDäMqwlíml™ë°£˚¡wè`vÄ|ÑÅáÑÜãÄvìâù˜úõç†òÇèÄèÉèÄéÜìÉöé¨ãú˚>˚a–˜/ø˜˛≥ã˜˜¢ﬂπ˜ﬂîIü:©P£\∫P≈ãõãöêöêyQ8 Jãyãxìzãxã{zãxãm®Ä•ãÙãÂ˜πﬁΩÊπ˜úÚô‡é°ëñïûçèåëãèãòÄåÄã3~Çä}fª¨ã2Ts3xWiÄsJ^vr†ôv¢y≠Äß|µsÚãµã…≤Çã•ãòéÄã!{Åâ{ÅïÜíÖû~åwéu†v˜ïƒ°˜î˜˜ï´ñàØßváu˚>kÄéhn†è°ÉÛÁ˜˜(É†èÉtNH_ã~ÑíÑëëîïéé∏≤™À«∑x∫Ynqvm|ízñÄóÄòãõå˚˚Xæ˜ƒ¯ªö€˜∂÷¯`¯Móè¶xwslÄ|®d^òZ˚#,˚˚˚⁄˚˜…∆™ª∞˚2jàqoâÉÜÑàxïâú˜úêåüòÇèÅèÇèÅéÜîÉöå´ãú@˜Öeãvorqmb|d%YÂËÛ∏Ú˜
¨Æt£®oëhe1|º¯!ºª˜5™€ﬁ˜C€€˜(˜v˘ëëúòïñÉçÇeàÑãläÑáÖàÑ{âÜY1áÉÖÇÅÇìÖîñóôëí˚Ö¸∏‘˜≠¯t˚˚˚˚˚˜˚˜˜"˜˜ ˜#˜˚˜ ˚á¸R˚TÁÒÚøÔ˜˜∆0$ZYmdbl[sXÉˆÎˆ˜)Éß•¢®™t£lnsuml°s™mã≥˜ÖΩ˜Òø‰Â˜◊Ò˜G˜¨ÊåÏìﬁ¥‹≥‘‘ãÏã“g¬L´R©NèLã˚ò{xäuyôàôáòáûà|¸¿cèÖf~~ÜÄà{uûäú˜ õüå°ù|é|è}évèö¯©¶â¢ßôó¢¥å•ººáp∂≥q•_Z˚0˚[^˚éY|ª¯æ˜ó≥ºÍ˜“Í˜%˜˝ï˜=ı˜-˜E¢ôåØåã†ãû{ç|ã&ã˚SGD42d˚ã˚ã@ï:∫MºJ‘m‹ã˜%ãÚ˜ã˜"˜9‰˚>ChXSäQø∏√¥‘Ó∏73|ÉYá|NyVYHHU∏»twºÜ…å¿1ã≥¯¬›Ã⁄÷Ä˜®Ñ÷—(˜s¯—ÑúíáùΩ≠∏∫óÑîpì[ãZkgØãabe`cÄèÄôóèìîëöîïîùòìáÜñ˚ê¸‚‘¯{˜±∫à»i∞ØkXô\;XoP\£áá i{tvÇÅÉ|Å|Äôáîà≠Äâpl˚ñtràÉàÅáÉÜÄm¢íú˜ôóîôòÇèÄèÇéuè†˜l≤çß©ß§ß≥úµË¢][˚óusáÉàÅáÑÜÄmüíù˜òóîôóÉèÅêÉèté†1ã≥¯¬˜Å≥ÿ÷˜ñ÷¯y˜≥øÜ∫g≥ØjZù\OPta_˜¡úé£rx[vÅyÇÜÄáÉîÜíâùÑùám¸¢|åfÇ}ÑÉÅàÅàÅáÉáããm†íúã˜	ôóìöòÅèÄèÇéÄéÜîÉöå¨ãõ˜Ç¥∂≥¢»‘¥^O˚YyåiÇ}ÇÅÜÇÜÑáãÄmüíú˜òòìöòÇèÄèÇéÅéÜîÉöå¨ãõ˚R|≥¯,≥å˜
˜îÈ•¯m~Ñ|t•ìï_¨˚#™(·˚ï}ûnûã¶ã∏⁄ìö∂‘ÆŸ°‹ú…í¶ãíú†êíìîãîãûåzã@{äy}ëàïÉúêvgg'}fw[r]la[∆9˜Dã“ã¬∏ã¶ãóÇïãY|ø˘'æΩ·˜˛ÿ˜°¯PFúK™‹◊”∫“˜,±˚ãßùâ£ñòã¨àóáóÑëÄíW¨DõNãHãN}X_]enTãOã˚†¯T˜ã˚hã"'X.ãXãXó`ßf£x©v∞ôÉÇòzyÇ{{\æUÆqe¿Œ~Ã”—õπƒΩ¥¨…Õ≈r¬]∞d©Qõ\ñ—ã≥˜lø¯(≥ã˜¯C˜)ﬁ˜Pg$ÉwÜÖyÇÖÑÖn∫ëù≈ùµÑ®©V|ã…ÆÆﬁñ≤˜Ÿíxïq∂˚	ãxkXñãlvüâõ˜ú¢ä¢óÑêÅêxïÉëÉüd˜ X˜5<˜R6˜%Ñóm√xã|ãu_~s;˚%<˚RS˚5˜˜˜$˜⁄˜˚¡ñrYã’˘ª◊›˜∑Í¯^¥ïà∑ïéõëúíöèìî†ãïãïÑìÅã}ã~ÇÅ^Z|ãGã˚kºÍ›“‹Õ€ÃÓ‹ã˜ã∆oº]≠]¨\ïTãKãLzZ`chmZãUãe°d¥ã£ã£óã¶òÇîÖïÅöáëû™•´¢ù¢´∞ó≤”…VA-.6LN˚.˚;ytI-ãqq°åûY|∫¯ª˜]Ÿº‚˜ÿÏ˜C˘'≈»∆éö∆°ë∆ù™ôÅèÇvàâÅ˚-É˚1òt¸	äyâu£ã∞≥‘ãıˆæ;(˚B?˚V@†Ãîéîãî¢vñvmyyn\≠c∞up∏¬Äæ”’û∫¬¿π´——˜% ◊˚UV|o\˚˚≥˘¶≥è¯´ñCÑãr´£îõûñ¯Y˘ØëõãümãsÇ~zÅ˚*ã≥¯≥˜à≥ÿ÷˜ı˜ˆ¨Æõ¢∂ûóêñëãöãõ~ã~ã˚	ä}ÄëàìÖìÖíÖÄ_˚˚ dm¯xúç¢sw^wÅxÇÜáÇïáíà≥}Ürd¸|{éfÅ~ÖÇÅâÅàÅáÉÜããvúâúã˜ôóîôòÇèÇêÇéÅéÜîÉöå´ãúæ·—ÆlÌ˚ãavjèãsyôâô˜úìå†óÉëÅê{ìáêÇú]ŸS÷I…òòYã≥˜/ƒ¯^≥ßœ˜îÂ¯N˜WÌüõç§®{år.¯Jßã´esÄÅ|y4:QMQ:a@s`U˚]k´è¢˜°2^èÄ\ÉÄâÖ~xùâö˜2öùçü†{åzè|èÉçÖôÜòä†ãô1˜˚î¿˜-‰˜ ˜˜¸.˚2≥˘◊≥∞Ÿ˜t˚&ì~•àíM˜l˜˜"˜#™˜…˜éíò•ìïzçÑwÉÑ{ÅtgpR{be+v'ã#ã˚&¥˚–˚òsìr´ãëãùçãïYã≥˘2≥˜´Â¯˘Yóå®w|~ÉÄ^j[zSázâhåãsãyùàöã¿ç†±äyöï}âs{¸5KâwBÑzâYãrv§âõ˜µ¢öç££_ãzåEèÜöŒY|∏˘7∏øÍ˜ÃÍ˜√|˜R»˜z˜*€zÔe—’cI»1˚QM˚~˚+˚*…˚z˜Q∏Cd“∆xvÃÜ’ÕÃê‘ù…»û≤⁄÷”≥@PûüLê?HLÜAyNNxd?@¸.˚2≥˘◊≥˜⁄ö˘}ÉóqèÑ»˚™˚˚#˚"l˚N˚áÉrÉÅúâíüìëúï¢Ø•ƒõ≥≤Ï†ÔãÛã˜&b˜F˜~£Ç§lãÑãzâãÅ˚*|√˜y∏˜	ªª˜5§€∆˜Cö÷Â˜v˘ëëúòïñÉçÇeàÑãläÑáÖàÑ{âÜY1áÉÖÇÅÇìÖîñóôëí˚g¸∏Í¯A˜∞«{æ[±´bQöWb`Éye|Ér{xzòÉöùóïîöû´ùì≤“ ]AêNéLãJÄUhWjj^L+ﬁ\‚”ƒ≠«±rgáy¥∑õ£ä¢ôÅèÄéÅéÅèÖîÉöå¨ãõ@˜$:`Öhinrn_~eqqïùwxúÑ°§Û˜¨ﬂ˚*|ƒ¯ºª˜5¶€ƒ˜C∞€Â(˜v˘ëëúòïñÉçÇeàÑãläÑáÖàÑ{âÜY1áÉÖÇÅÇìÖîñóôëí˚g¸∏‘˜˜Dœì“íÀ§«¢«µã”ãµp∞h°mûfíhã˚(ã˚	˚ã˚'ã˚Ù-˜ãøãºú∂®†ôµÆãßïÇìÅpi7ã˚;DΩ›|Ö∂˜ä≈Ò˜ª¥tV˚˚My9ÉYãæ˘≥ÁÂ˜J˘≥Üê∞ôòêñçú†xåz˚zxãuxôàöáòàüá|¸¿céÜf}~ÜÅà{uûäõ¯bü†â°ïèìòÀìñÜîz{ÖÉen{Ü[Ñ˚ÖUuå\äxô}ñè£ãõ¸.ã≥¯$≥ª˜5≠˜C˚÷c0˜v˘ëëúòïñÉçÇeàÑãläÑáÖàÑ{âÜY1áÉÖÇÅÇìÖîñóôëí:¸∏»˜JùöçüôÅèÄèÇéÄéÜîÉöé¨ãõ˜\∞é∞Ö∞ùàãßrÄyÜÄ|Öf{ÅÅÜáäáãÖãóáïâ∫ÅÉqé_˚gbÖ{nÉÄàÉÜ~wùâõ˚zãΩ¯	Ω°˜˜9ı˜‚ùüäûììûì¿°íàëÉ~Ä|ÇÑÅydk˚xÄéññìôíìÃﬁ˜˜+†•∫√ã≠™eÜv˚ÑÄzçÉÑÑÄÑ_à~äÇÑlùãóãíöëì¶±¢é∏ã›î£è|}}|ÉÅ˚˚%ng#˚ãcj∞ã£˚*ã≥¯≥ì˜˜d˜˜Y˜~˚˚+woååo}ÅáÉÖÄwëäö˜òôçõ§fÖã®©‘€¢£úyúy›8ãuzrÜãyzïâö˜ôôçûóÑêÅê~ëÅéÅï{ôvß~ú˚˜˜˜%õ¢éå°óîêíêñõÇå{/}ä|t™éãxmE=utv¢=€ßú£éùõÇå}˚	|Çä|{ëàóÑ®|ôsùqÂ|≥˘/≥Ù∆¯@∆¯‰˜PU„V‡T‘Xœa√˚˜Coä˚~{à{yùâòà∑Çãje¸[ì}XÅ~àÄÜ{{ñÑö˜ôóíõ†}çyènìäò¶¯Ø˜
˚Ê˚&Ë˚#∏FøI∞AêÅîxôãßãÜ≠ãû¯’ïä®éïèòõèóêñèôèãöãú}ë|ã˚}~ÜzwõâõÜôáïàé{éäqã~¸B˚aÿ¯Ã≥ÿ˜Â÷˜ ¯¡≠£°Æ©s°mlrukmür´ƒ˚~∂å∑Ö∑ôâÖózzÄÜ}Ñf{ÄÇááâáãÖãóÜïâñâôàíÇï}ãrãz¸Yä_gÄ~ìã{tx{st§}†¡ª»πû£¬é◊«—|ƒ˘"æØÒ˘A˘äôâôÇòÇòkú}ìO™KõHã˚rã˚=˚Uã˚lã˚a˜9˚(˜\ãÀã–ù¡≠§ö÷ƒã¨ãòÇñ~ãzÄzÅÅMMNh34=™‘Wa«wÂ”‡§‘¡Õœ¬ Ø„∫∑~p±¥mõm†`ëìqõãüãêúãú©ã≥˘øÊÂ˜—Ò˜I˜Œ˜6®∏]˜˚8ãTfXñãlv§ãö˜(ôüãüõ}éêlôÑô}™`È]ÁGŸ›∞›«ãÔã¬oª\©^©XêVã˚Àzxäuyôàöáòáüà{¸øäcèÑe~Üàãzãvüäõã˜úüã°ù~ç~ë~êyçö¯´†äßûòòùºã¢‚˜|˚˚'˚fu zÅã≥˘æ˜¶Â¯ ¯˘∫â†√£≤ÜÑ¢∞Äò®tîÉñòãóãëïãñãìâïâìâôÉøÇïÜêÑãÑå¸øsàC}âäÑâÉÉëÄôóóôíì™•ùö¥î£ê≠ê§ãºãÜtãd¸ïdéÇeÄ}áá{vûâú˜úûå°ú~é|ê~èxèö—|‰˜˚≥ç˜˜s”˜sÊ˜‡¯mÄväzqÆíãb'S˚"M<lπwø{¿|∫tŸã∫ã≥±~ã•ã°Ñåyã*}äxt§íí]ö+ß'≥3ïv∏&©ãºãË˜uõ∑ö_ﬁ˚uªãñãëèíìù¢ü©ô•≤“™È°⁄ô¿î¨åîù¶éêçéãëãõ{åã@}~äxq≤ñãX=N˚>ZJ[ÿJ˜0‰∂∞}®úÉç˜*|∑¯£ºÌ∑≥∑˜9”˜N‘˜(∑≥¯˚f˜8˚?˜^˜^˜8˜?˜f˜f˚8˜?˚^˚^˚8˚?˚f∑˜M˜$˜,˜F˜F˜$˚,˚M˚M˚$˚,˚F˚F˚$˜,˜M˜ÅbÌ†®m¬<ã_ylïãpr°åùÕú°ä§ôÉéÄíwñåïÇ°v«t¨eºª£∑∂ã≈ã≠x≠qûn¢géhã˚Hytén{ñáòÜìâéÜ}˚√mà}ÄààÇÖ}o°çûŒú¢ã£ûè}èwêêîü˜ƒ™ôìΩÖπ◊ãH@˚sRÇÉÛ˜QˆÁ˜˜'˜±®§¢®™u£lnruml°s™å˚π†èÉtNH_ã~ÑíÑëëîïéé∏≤™À«∑x∫Ynqvm|ízñÄóÄòãõå¸†v¯è˜Ñ‡˜˜˘qtxpj†{´åúêÜxNOgã~ÖëÖëêììéé¥Æ¶≈¬±z∂^˜*ã≥˜‡ø˜†≥ÂÂ¯EÂ˜H¯¯E˚ûdéÇdÄ~áá{uûäú˜!õûå°óéÅêÇêÄê}ëÜëãö¯∂≤àî≤ñôèñèú†xå{˚"{xävyôàôÜôàûá|˚Ç¸E˜^≥âí∞óòêñéú†xå{˚{vãuyöàôÜòáûà{¸ødéÇeÄ}áá{uüäõ˜úûå°ú~é}ê~êxéöY|∏˘4ª‡Â˜ëÍ˜…˜ˇÊÜ∆J1\yWikli[Ä^AL¨€Ü¶âÖûll{un˚˜#bÊŒÃòµ¡ø≥´»ÕÙ,—-ùŸ°Ÿ¡Â˜ Ã˚ PJxf]ptqiek£w™ù°î†óÜöãö«≈¢ø◊Œ\;b`nnefbáZá{â_çãrãvüáúäY|º˘1∫ª‘˜Ì‘¯¯+‘±·¡Êˆ˚¿0PQyf\^imUR.–VŸg6i)J%˚˜U˜ŒÀö≥¡æ±≠∆ ˆ4À/Ø˚P⁄h˜j!-!]9cdê¢ii£s≤¥Ê‘≈ÿ¨ÃÿG£˚≠‰›‡º÷‘ÿ]:DBZRl1ã≥˜…ø˜´ø‰Â˜G˘!úõïµ˜8¬≤rq§Öëò|ïïéíîç…áùÉ¢kê¸OzxävyôàôÜòáûà|¸¿äcèÖe~~áÄáã{ãvûâúã˜úüå°ù}é|è~èyéõä˜™˜d©ïãw°Éìèáóüâßòåõï≈lÄáÜÑÉyuÄäo˚c˜fã≥˘ ≥Ì∆¯ì„¯:˜z˚P¯UÉùÉØrä˚|Ö{hÃ¨ãP¸ºjãÜl~ÜÄá{uùãù˜òôêöûzè|ê{ëyéàù¯œüYÌ˚Üˆ˚yëìyõãúô´óë÷˜/˜$˜‰¸†bìág}~ÜÅà{vûâõ˜úûå°û|ç|è}ètéõ¯∆∞íë≠îóéöèö¢Äçz˚tÑtxÑ*˚z¸ã≥˘ ≥·Â·ıdéÇeÄ}áá{uüäõ˜úûå°ú~é}ê~êxéö¯øå≥áí±óòêñéãúã†xå{ã˚{wãuyôàôÜòáûà|˜*|ø˘%¿∞Ò¯ôÒ¯|˜n˜,˜7˜kÒnÌC’”F-±(˚o˚˚B˚g%¶-“@EŒÂgÎêø;G¥À_^Ãz⁄ÿ÷õ◊¥ —∑“∫ﬂ⁄‘bKππKú2=@y<_NJ[Cb:˜R|∑Ë∆¯¬‡∑ø∏˜‹¯Q∑¿¯˚f˜8˚?˜^˜_˜8˜?˜f˜f˚8˜?˚_˚^˚8˚?˚f˘E˚M˚%˚,˚F˚E˚%˜,˜M˜M˜%˜,˜E˜F˜%˚,˚M˚Y˚aooyW(bÏÂﬁ¶˜Ó˜z!ã≥©á®†âäùå≠{òg©Lõ^ã˚ã9˚ã˚ã˚Ÿ˚	˜ã√ã¬ü±πñóô†ãùãöò}ãzãÑÇ}—ã≥˜lø¯(≥Æ˜5ã˜˜$˜C˜˜)˜\˜ó˜v˘ëëúòïñÉçÇeàÑãläÑáÖàÑ{âÜY1áÉÖÇÅÇìÖîñóôëí˚’˝ªÍﬁ˜Pg$ÉwÜÖyÇÖÑÖn∫ëù≈ùµÑ®©V|ã…ÆÆﬁñ≤˜Ÿíxïq∂˚	ãxkXñãlvüâõ˜ú¢ä¢óÑêÅêxïÉëÉüd˜ X˜5<˜R6˜%Ñóm√xã|ãu_~s;˚%<˚RS˚5˜˜˜$˜⁄˜˚¡ñrYãø˜–ø˜òø„Â˜F¯˜Y•óãyüÖëíÑî¶â£üäöíƒpÄáÖÑÑxvxäp˚T˜J≈áûüΩ˜5∑∂li¶ÜèêàìïëëïåÉ»àüÉ°rë¸Ozxävyòàôá®Üéus¸§déÉe~áÄá{uûäõ¯f∏åáâîæéùí©ãúãîÖìÅã~ã|zÇÉhjhuXã˚*;É±›Ωq≥˘:≥å˜'¯<˜¯¨˘p|}âykÃóãYMJ˚DsKi1f2W:W„cﬂgÂpœR˜3ãœã´ñè¶ôîèóìãñãù{è|ã˚#~xàzl∞ûöJ•˚≠˚¥ ≥#º"À.î~ñ|ùãüãû®ïôÁ˜Ï˜ï≤˜´˜êôëîóïìíïíãòãôÄë~ã˚é†v¯V∫˜b∫Ω∫˜b∫˜Ú¯Ï›Gœ98GG9å8ŒHﬁ›œŒﬁ˚ë√ä∫∫√ƒ∫\SQ\^SR]∏≈Yn≥˘‘¯_€¯_˘'˚ß˝
áÉàÇãÇt™Çû¿è¿µö˜r¯Îêóòßãñ†wÜ|¸}yéÅÇÅåX}â`ã{ât°ãùèööçÃì≤â¬zú¯jó˜å≠˜¿˘endstream
endobj
22 0 obj
<<
/XHeight 764
/Ascent 730
/FontFile3 21 0 R
/StemV 75
/StemH 0
/ItalicAngle 0
/CapHeight 730
/FontName/TWGKIW+Souvenir-Light
/Type/FontDescriptor
/Descent -17
/Flags 34
/FontBBox[-157 -205 1173 971]
>>
endobj
23 0 obj
<<
/Name/F3
/FontDescriptor 22 0 R
/Type/Font
/BaseFont/TWGKIW+Souvenir-Light
/Widths[300 0 0 0 0 0 0 0 240 240 0 0 300 300 300 520 600 600 600 600 600 600 600 600 600 0 0 300 0 0 0 0 0 720 0 720 740 600 560 0 800 260 0 0 600 860 740 800 620 0 680 600 640 0 700 0 0 0 0 0 0 0 0 0 0 500 520 460 520 500 300 520 560 240 220 500 220 840 560 560 580 520 360 400 300 520 460 720 500 480 420 0 0 0 0 0 0 0 0 0 0 0 0 500 0 0 0 0 0 0 500 0 0 0 240 0 0 0 560 560 0 0 0 0 0 0 0 0 0 400 0 0 0 0 0 0 800 840 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 280 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 720]
/LastChar 231
/FirstChar 32
/Subtype/Type1
/Encoding 20 0 R
>>
endobj
24 0 obj
<<
/Differences[46/period 97/a/b 101/e 108/l 111/o/p 114/r]
/BaseEncoding/MacRomanEncoding
/Type/Encoding
>>
endobj
25 0 obj
<<
/Length1 1099
/Length 1099
/Subtype/Type1C
>>
stream
  OQGELM+Souvenir-LightItalic   M¯ ¯¯¯¯È•ˇ$º˚T˚aÔ˙Z
 ãã
 ãã   Î   Á   ¸ö  < C\hITC Souvenir is a trademark of International Typeface Corporation.ITC Souvenir Light ItalicITC Souvenir    Q S P C B M F  	   ´Y‹Kú*˚ÚE˚U‹æ¯∆˜ ⁄˜õ‰˜)Ùñœî”© •ƒµøœã€ãÆKãAã#P˚˚ã_ãm¢ÅããÖtãÇãf€Ü•ã˜!ã˜˜1ã˜˜J‡˚)UO5iîØêØ±öä†xvWmÄxÇÜ}Ök√¶XoÜnáp{˚ s˚$s˚ÜwÑÑxÑ~Ü|Üz{üáó˜ôôëõ¨bwã∂≠íØê¨˚éã≥˜˜‹˜◊˜
ûåêíåùì⁄¿˜∂Òã£ãòt†ã¶ãë©ã°ã™}†iã`ã]lpkpj~eÄcçïì‚ã§áøhãzBdvn¿úãNX|@ÅWy0â~Öpã~tôçü1Äº¯ªù‚˜€·˜yÄ˜*˜˜˜,˜.€˚˚)˚˚˚*˚
Í7˜îº3^»ﬁ˜	–˜˜‡∂D=˚ B˚˚˚Äæ¯»˜Ñ≥˜"‰˜Xﬁ«ÚásÄ]tÅêÉñú¨±ôñd§ª{∑˜,˜˜)˜'ˆQ‡˚DVfSdèõ´˜Kí≤ô‘ã±£Üã~v`tÄzÉ|Ñ{p∞òdoÖnánS˚¯˜Ö˜oﬁ¶BC$J˚˚HgπÀÔ¿˜:˜˚Ä«¯	¡ö⁄˜ûπ¯^¯JåèåëêìÜìÇtplz~∞raù_˚)˚ ˚4˚)¡0ˆﬂº…“™Ö4ã{ép†ãüŸ∞£™Ylã¡∂ô⁄í∏˚Ä˚uDq“»Ï≈˜$˜ƒØcS,[˚J˚É≥˘A≥”‡˜i¯U∏˜ñçïçìãñóÇîp6dlÄóàìàõÜíÉynSál;¸nâÇâ}ãÇç~öüﬁ™•£hxãµ°è¢è†˚*Ä»¯∏öﬂ˜¥‹˜dÄÀÕ£Øøõñ¥ß£îÉíÅrV=ã˚/P∂Ìì’íŸí”§…°ﬁªã÷ã®z•túl°_ígã˚,ã˚*˚"ã˚.ã˚⁄?˜ã!˜åÎûËÌÎ≠¥x`ç-è˚peFÉ˜¿ÛÏÉÆ§©≠£z¢rgqnhqúv¶|ö¯gî˜î§˜¿˘endstream
endobj
26 0 obj
<<
/XHeight 757
/Ascent 732
/FontFile3 25 0 R
/StemV 79
/StemH 0
/ItalicAngle -9
/CapHeight 732
/FontName/OQGELM+Souvenir-LightItalic
/Type/FontDescriptor
/Descent -15
/Flags 98
/FontBBox[-192 -205 1263 966]
>>
endobj
27 0 obj
<<
/Name/F4
/FontDescriptor 26 0 R
/Type/Font
/BaseFont/OQGELM+Souvenir-LightItalic
/Widths[300 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 520 540 0 0 500 0 0 0 0 0 0 300 0 0 560 580 0 400]
/LastChar 114
/FirstChar 46
/Subtype/Type1
/Encoding 24 0 R
>>
endobj
28 0 obj
<<
/Differences[32/space 44/comma 46/period 49/one/two 58/colon 65/A 67/C 69/E/F/G/H 78/N 82/R/S/T/U 97/a/b/c/d/e/f/g/h/i 108/l/m/n/o/p 114/r/s/t/u/v 121/y 146/iacute 151/oacute]
/BaseEncoding/MacRomanEncoding
/Type/Encoding
>>
endobj
29 0 obj
<<
/Length1 4731
/Length 4731
/Subtype/Type1C
>>
stream
  FUJGQA+Times-Italic   C¯ ¯¯¯¯Ä˚=˚m˙Ö˙
 ãã
 ãã      ¸  O¨  Z }âé002.001Copyright © 1994-1997 Stream Technologies Inc. All Rights Reserved.
 Turku is a trademark of Stream Technologies Inc.Turku ItalicTurku  &  5 P M Z Q D B E J V N  O G U  H S W T  4 F '  ÿ / ”  ) ( 6 & I " 3 C  $ (   Y û Îx˘F¿K¥D	
úç´Oµ$î¿	G	ß
 
t
Í_„9–C∑;Œ2¥Z∑-†v¯ˇÆ∆¯—˘˘"¸ßa˚.ùá°∫ú§•ü§¨¶ë˜˚#¸•}YszFÑ{˜∂õ9ëÇè´ïë•í•˜ ¯á¡÷®rKÅäÇâxúä˚*ïv¯Yv¶ﬂ˜¶ﬁ¯h˜πËU√2˚(˚*˚0˚-/¬WÎ˜ ˜*˜<˜8´)B˚m˚[k∞¬Ó›˜p˜∂ßfP¸ïv¥˜Ç˜´˘;ÜêQ{à9{§ç∑ärÑèñv>"¸v;à}ãziõy™¡ß¢Ò—îUCwxuãÅÜëïíéöì©˚b˚Lv˘v˜‡Èc≥–¯>¯≤u£h‡v{|w–Z¡óãdP,˚/p]w˜Ö¨N˜qyãvE}ÅVzéüìåî¡§Y˚lºöGïV~{Ñ|tmxqplwwÄÖÇãwã}®pãtãz{ãuãpüy™ã∞ãº≤–‡˜	˜#˜˜Éã⁄˚*˚Mv˜Wû¯∂¯Â¯i˜…ﬂaºBL[l=TâéßÓáí˚0uéz©é≠àãpÑÜsÇj˚¸N~YÖÖ[Ü|˜bö\yî°©®ìÆ}¶òà®˜!˜0˜=˜+1ì˚(˚ ˚5'ltö°πª˜(ùπÃ§ƒºø≥°mW˚bÄØ¯5w©‡¯<˜¸Ωa´H˚%˚ ˚'˚.)øUÎ‘…Æ‘¿{îcZSk[ãSh∏“˜$Ï˜Ò£öÉ{|Çãruõ|£¶ûû•˚*Äº[ª¯°úﬁ¯pÔñ~~YSyãÑÜêìïê¶ñµÿ˜∆ÖéLÑÄ[äåÄÆoûdã˚˚1˚J˚-=ÆbŒ—≤©˜„çà{LÜqãwoò®±¨•ﬂÕ˚˜î3,˚z!drß∑ÂÈ˜q˜Æ¢qd˚*ìvçª¯¢ö·¯¢˘;ÜêPwâBÇyøñávÇÜrÅg_˚3ââÖ≥zöbã˚ ˚,˚`˚B≤^À–µ©ÏœçâÇeàvãumú{©∞æ¥‘¿ï]Vwy|ãÅÉîñìãåî≠{˜ê˚" ˚D4dt¶∑ÁÏ˜o˜´õua¸ñv¯ƒı˜;Ï˜ú¯Ô©v¢povtmm†tß¶†¢©n¸à~ñj]jlyãÉÖëîíãèö¬‰˜÷àçH~sàFÇ{øäñáyÖà{Üyd˚$l˚äÖãreõx©π≥´‹¡˚*Ä¿mv¯Nv™v˜‡˜∏¯o˜ }î[Nyy|ãÑÖëïóçåòºãê†Ÿ˜ºAa˚rT`HP/XUnãqãç•çìÊ¯ ∏àéQ}zà@Ä}†â≤ílÉãäÇgY˚W\ÜpãzgùxØ–ææ˜O˜çh˚Éhw¯lúy©œØ–ªÆ”óv©v¯ø\∫ó˘Fx˘RÙ}óZOxyzäÉÜêïîåêí£ƒ˜gî≠ë©ãòØsßk24˚Haâç¶„ï±ãúØt£iO?D˚8àéƒ˜[àé$vååPÄ{¿äñázÉçë{M8˚ ÷™üﬂ…„x—º¬ª®òìÇ|Éåç|Tãâ;˚∫◊≤˜,†¬ªœ∫œ¡ª¶ãóãîÇã}ãÜåéÄ^Z˚Z}Qáz~¯oö{¶π∫∞ÿ¿˚*óv©v¯Nvô¯`¯nÛ|òUFÅÅyãÇÖíîíê†ï±∑˜4ó∑î¥ãö∞q§e,4˚&H^âçÀ˜eáç˚tëå[Ç{æâòÜx~ÇnÖvãÉl@˚ß÷¥˜$¢√º— „±¨ØãòãïãzãÄÖlÅf`˚7{PäÉ|lõ{´π©§„À¸˚Mv¯Ô´˜x°ØÍ¯:¯˙±g¶Xaexdjibu\j#0ÉkÂ3¸9t˚lX_ãÑëïîîêãô†zösw}zsi¨q∑Â–Ï˜Mµ‘˜’˜ ë´ ˜0¶±”¬ôïÜÑäÜÅÄã|sö{°¢ùù°¸ñv¯+¨Ø˜ò˜º¯B;ßÚåçãçãçêàèÖÖääÄÇ\Sbib{mÄáàãÅãÇãîãÇ÷B˚ßt5åéãÇuä†y¶§£ñü¢ùõòú≥ƒ~ërlpj{}ãÅÖëñêåçèõﬂ˜“ﬂÄ˜¶˜˜∑™r§mlrrlm§r™©§§©˚*˚Lv˜¯°˜ã°ì¬¨⁄˜*»j⁄¸¯l¯≥OzvØã; 0=/U†n≈pPcyxt}íÄû|\gFoGHÕ]Î˜ﬁ√‰˜˚j{ã¿ñ£®òôöÜãô˙‚ËﬂÿòäéÉ±E}.R5NeußºÊƒ⁄ÕÆür`¸o¸MVQa?>X≤∆Øñ¢©§úüùòêì rÖö”oüxd˚ô†v˜ËÒåv∏¯¯0¯™xünX@7(^Çwäçº˜[àéWÅWÇWÇ{éûìåì†òÅy~ÖiÅh:˚π◊∂˜ ö¥Æ–∞’µ¿†ã†fã∂®úû´˚bèv¯_v˜‡ËYΩ–¯=¯≠s•k‡u|~w–^∂çãh`J˚B@lkÜ˜Ç˜l˜
ïààãÖ~zÅ})}Øå¶ìö^õ[õ˚0ê˚+ånãäîãùãŒŸóò˜˜‘˜ã…˚ôìv¢v¯A£åv˜ ‘πÿ|¯¯O}}ÇÑá~|nqúãcC[aJ-˜?ã@[nkaRl≥Ïz|¸w˚4öõíëêñ|≠™xã±ﬂ…¬÷Í˚Ÿã‘¨¢ü≠Ω´g=ï|õá˜˜¨≥sßinvxpzíù{ö}êÉrurVgïx‡º∂¡ã∆˚*yÆÄv˘¨åv˜‚˜„º¯è˘0tyÄ~Éyºfz§ã>˚DD*Pór˜˚¬Qõq]@SQB9K”Ëíãëçówå¸j˚sú£íóïûºµ¿fã∆˜‰·˜Õt≤/Á8ﬁ{•∏»∂µ „Æ^˚	èºúâ˚bÅ∏¯¢™·˜yÃ¯/¯
∏o¢T˚˚2˚9˚&3æV‡Œ’≤œ…óCQk{`ãSe∞¡ôéüí•®è˜,†Ú◊ã‚Jí7+G˚vù∑∞Êœ‘¿é†åö{td†v˜€Æ˜ó¨ì˘˘˘"¸Ü{œÖïÜn}ÜpÖt˚¸O{RÉÑRÄ{˜êõQèyñ®ñåèì©…˜s≈ä¡äπéãYxâ|ÖsúÖ◊˜xëZ,ìè˚BàÃ˜}ë¢ïéÕã˜,™~M}ãÇâxüâ˚*†vº˜¸¯-˘0ëâçáÑ2v{+{†çØãã£åòÄxÉãÖÖw˚¸ÇÄeÇá0}˜´ôtåKá∞íâÉ†÷˜#¯öèöçîãè˚*ïv¯Yv˜Üv¶ﬂ˜.˜s$ﬁ‡Ë¯'˘†{öwÇÅáÖÖ˚6˚4Æ˜@ˆñíêîãñ¸|˝Ù¯h˜πËU√2˚(˚*˚0˚-/¬WÎ˜ ˜*˜<˜8´)B˚m˚[k∞¬Ó›˜p˜∂ßfPúëvØv˘"vw˘˘k˘õ˚[{¬áôÅj}äÖÇh&¸â˚d¯É˚3{ºáôÇ¢a˚¸7h˚Å}QÅ{˜[õUëzï©ïè§êú˜¯5ç˜y¸∂ù˜$¯çØ˜ëï…ñ¸ñv¯Xv˜Üvº˜N&˜s]Ë¯'˘†{öwÇÅáÖÖ˚6˚4Æ˜@ˆñíêîãñ˚˘˝˜Ú~ñj]jlyãÉÖëîíãèö¬‰˜÷àçH~sàFÇ{øäñáyÖà{Üyd˚$l˚äÖãreõx©π≥´‹¡˚*ã÷¯•‘¯‡¯W¯éÌF‘-*?Q%güÑ≤Õµß…ã“¿WDP`C%˚˚e˚tz˜˜Ω˜zírXv~Uã˚Rê˜U˜U˜
˜
©∫ãœ”†v˜⁄µ˜≤vÉ˘ô˘ë˘õ˚ä{ÀÇëÑp~ÜkÜz\˚9˚∞¿˜Xòª£ùÀìõ˚¶{óäîäëä±ÜòÄãsã}ápÖv˚¸O|TÑÖQ~{˜äõRí|î¶íåîçíŒ˜à˜±J˚Ä}Xw}HÇ{˜•õJë}íßíçîçî˜¯vöƒìí≈ï”y±¯¯Æø˜¯Â˘e˜√ú˚ùz ÜöÑshf˚yolwe|S˚?”˜˜=˜Ö˜ZÙÕR!ìùàº˜Y|è~uyoãfK≠ã@˚g˚V˚Z˚k˚8˜˚ ˜E‹‹°≥–ª˜Oô¬õóŒê”yµ˘
vÒÊ˘ê˘õ˚Y{¬ÜöÅlÄázÄd?˚Øc˚*IG˚ ã9RªŒø®Èôæ ˜uö¡¢ú ëõ˚•{—ÖîápÖjÇlR˚`_w8ã`)ÊD˜˜ﬁ”˜*∑ﬂ˜±≤˜çè»òdã¨˜πÆ˜ò¨ä˘˘˘"¸Ñ{™â∏åa|áqÖv˚¸O|VÅÅUÄ{¯é…˜7zì<˚Sq˚9ãXsñ¢ïê†ó∏æ˜N…à‰áóáãhÉä~áiùÖœ˜}yè_+äã˚@âÃ˜}í£îéÃã˜0ßHÉãâx†â˚*óv©v¯Ovû¯]¯pÙó_QvwzãÉÑíïñëôçìƒ˜eïÆë©ãò≤pßfKFM˚#-âç˜
¯KÖêL}wÜBÉz§åúå§âãtuj|P˚¸ã÷±˜)õµ≤∆¡‹Õ∆ÆãõãóÄã}ãÜåãÉnW˚S}WÇapú{ßæ∑Æ⁄ªd†v˜vØ¯+vX¯˚¯»õSéÉï”,¯Ãq˚µ¸âA˚}{bÉ{˜Oõ\ê~í¢òì•ó¢≈˜˜pü˚åÅåÇãÅgx~Pä{æ˜ö˚V˜(˜òçd†v˜‚ß˜õ®¯uÙ¯ﬁ¯îËCº˚˚ç{™Ü¥ébÜnÖw˚¸O{QÉÑTÇz˜áõTê~î©óéûì©ƒ˜eÀÜ˜˚Ÿ˜(õ_éxùwø.˜â˜®ÀƒÁ"ê&KU˚	sÑåêoÃ˜yë°òë∞ãÿµdF˚*Å°¯º¯‡¯n˜‘‘[ºD2V:J^äç¯ÜêUÇêã#|{†â∏ënyfá{˚¸äàr’n…˜)˜:˜B˜06~#˚˚S˚h|ó¶ÏÎ˜â˜µßiW˚—Ä˜˜|˜Ω˜Ä˜–˜ô¯™r§mlrrlm§r™©§§©‡'˚Î™r§mlrrlm§r™©§§©úy∏¯ÚÆâvÕ˜˘E˘.vzÅÇÜvjf£ã4˚g˚V˚[˚l˚5ı˚˜0›πÛ‰zôWUEJ˚ ã˚M◊˜ ˜8˜˜v˜RÁ¿S!îûáxû¯Aô˜g¢íã˜°ç¸sé°
¢
_˜é˘endstream
endobj
30 0 obj
<<
/XHeight 677
/Ascent 684
/FontFile3 29 0 R
/StemV 23
/StemH 0
/ItalicAngle -11
/CapHeight 654
/FontName/FUJGQA+Times-Italic
/Type/FontDescriptor
/Descent -205
/Flags 98
/FontBBox[-169 -217 1009 884]
>>
endobj
31 0 obj
<<
/Name/F5
/FontDescriptor 30 0 R
/Type/Font
/BaseFont/FUJGQA+Times-Italic
/Widths[250 0 0 0 0 0 0 0 0 0 0 0 250 0 250 0 0 500 500 0 0 0 0 0 0 0 333 0 0 0 0 0 0 611 0 667 0 611 611 722 722 0 0 0 0 0 667 0 0 0 611 500 556 722 0 0 0 0 0 0 0 0 0 0 0 500 500 444 500 444 278 500 500 278 0 0 278 722 500 500 500 0 389 389 278 500 444 0 0 444 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 278 0 0 0 0 500]
/LastChar 151
/FirstChar 32
/Subtype/Type1
/Encoding 28 0 R
>>
endobj
32 0 obj
<<
/Differences[32/space 67/C 97/a/b/c/d/e/f/g 105/i 108/l/m/n/o/p 114/r/s/t/u]
/BaseEncoding/MacRomanEncoding
/Type/Encoding
>>
endobj
33 0 obj
<<
/Length1 2228
/Length 2228
/Subtype/Type1C
>>
stream
  ROZBKM+Times-Bold   @¯ ¯¯¯¯˚<˚n˙z˙:
 ãã
 ãã   ˘   ı   ∞  è }áå002.001Copyright © 1994-1997 Stream Technologies Inc. All Rights Reserved.
 Turku is a trademark of Stream Technologies Inc.Turku BoldTurku    $ F G B M  T P D J E Q S O V U H N C    g œ/∫ÈÍc´Ù=§~„;y7ÿC“y∫˘	≠áwº˜E˚E˘`§Ù˘A˜m§;4Ig;ã˚IÒ˜a˜k»ˆ˜Á€E˚«§Ù˜~pk~}yËoBΩã#˚V˚)˚0˚`˚d˜%˚"˜j˜ŒÆ˜Ó˚c}”˜O∞˜4©§˜$˚$˜˜˜Ù¯<˜tôaXo{_ãBc ˜Ü˜è˜*ÑJÿ˚	˚6'˚ ˚&›'˜ﬁ¡≠Ê«Ï˚˜?˚˜†ªΩ•ü{líëuãÉé8˚“ã§¯∏˜zw—˜√˜¯¯‰≈P¥7RYwjomhÇa'S^√˚‡`Ä^ár˜©§Iä{öÀ˜Õ·∏5˜¡ô¢¨ùòÑÇäzvzãqm•s´≥££±˚+}“Zv¯[™§˜&˚˜˜˜¨¯z∂}†ÅÅààáäÜã~Ñîõ˜ô‡>ø˚˚>XBa£rµ≤ß¢´µlìãûû©ú≠ƒ§pMB¥1q˚E^˚	Nπ^ ≈πüΩ¬ÏXï°yøµ¶ôµ≥¥˚Vƒjn{Åqou®≤≈≤≤›£¸	ã§˘wÕ˜˜ë§kå{ü±¯‰˚QrØáô{e¸ëezwjär˚ö}≠v¯Y¨äw§¶qÔ'•˜gÏ•˜¸˜˜?˚~rãÒ™™•¨ƒ¥f>§•µ˜&t|ÜÖÜ}•tk†ãX.IO8˚3˜Åíã.emp_£F]∑‰uÈp˚:§†îîíë•ûƒnã¿ÁÃ»„˚+~©¯=©§˜'˜1˜&¯o˜y˜ ,Ú˚˚,$˚ ˚!È&˜˜È˜!˚&å˚3wUPQw¡˜3˜2ü¡≈∆üU˚2˚c~Õ¯™§˜!¯AÊyùfbp|cã7R‰˜ı™ ¿´ìÄUåSåõu≤µ•§≤…Gª3˚)"˚&˚‰)˜◊ÕÆ–º¸	ã§¯Hw˜éwœ˜˜j¯˙µhÆa`hha`Æh∂µÆÆ∂≤¸˙§jè~õØ¯˚Ss∏ÄíÑa˚πbÉÉ_År,}√¯
√˜H£§˜(˜6˜¯©û£_é|ô¥¯”˚lsŒÜïÑ]˚Lº\rò^˚:!˚$˚◊*˜ ºØùª∑J–û¶éÓï˚ZË{aUbUr≈˜˜¶«√≠™sfô,˚Lv˜T¬¯
√Äw’˜ ˜5˜'Ï¯û˜á˜?Î!MfsUpà‹Œ˚Rr∑ÑîÅa¸âbÑÑ[Çs˜§†PéyüÕ˜!]∫•~∂˜ÿÚ˜-˚'w˚pQQjrü≥y˜áÏï¨»øø£N˚˚cã§˜¬˜%5·Äw›˜˚˜ ®¯E¯∫j©Y[anNcâ∏⁄˚Qr≥âò|b˚∫dÄaÉr˜ù§§NéÄò…˜Pø¶∂´‰©èPã¡±•¶¥,ã§¯ŒÄw‘˜˜˜ÿ¯≠§h}ú¥˜ã„X¡8U`tU^¯Õ˚SrµÖïd˚ªcÄ~bÖr˜É§ié}õ∞˜ûÿí±æª≠ùoU˚ÜfÄ}gÜr,~Ã¯§À˜˜˜¯™ü¢bç}öµ˜˚˚]røáïÅ^˚ÆifzÇod{üæ˜Ê˚Or¥ÉíÇa˚é2ºX‚≈µß∞µJ…¢ÃèÃë˚“îv¯A∑”˜˜ﬂÓrósaÄÅvãq~û±˜¡Á∑/˜=r?&okMUqø˚ÿI∂d“ÃÆ•‡∏˚+˚b´˜˜„¶˜k¡Ç©ß„<˜˚˜˜+˜f⁄È@¯vSŸO∏#J=vì©¢©¶• ÚÄÔŒ≈·µÄßnß€¡˚Í@úXvèe˚8J-G∏SÿpäÈ@;mfeXc§qø}äÏ@QÇjqeQ◊g˜˜>·ΩÔÍÄ˚E¯/xg\^w≤‰Èû±∫πûd.Ï@Ì¸1^Tq)5[¢∂¢îò•û˜@¬§{i˜Iã§¯ŒIÕw—˜˚˜˜˜˜˜´˘æ§dåÄòµ˜é·W√:QctKYÕml†FMdsNbäª‘˚RrµÜó~c˚∫bÇÅ_Ér˜Å§ßjé~õ±˜ùî¥æ∑∞úpR˚ÖaÅÄdár˜~§iç~õ±˜ûÁî¥ΩπÆörQ˚ÖaÄ~fâr,}´Åv¯D¿˜`w“˜˚˜ ˜6˜&z¯õ˜Ü˜?È˚[k}bb˜ó˚Ur∑ÑïÄd¸Ûó⁄√ˆ`æ¨}Ω˜ÊÛ˜,˚&{˚$nKIen≠∑˜õ¥ö°û´»´H˚xû¯aó˜_õ˜pî˜üì¸ué§
§å
_˜é˘endstream
endobj
34 0 obj
<<
/XHeight 921
/Ascent 912
/FontFile3 33 0 R
/StemV 25
/StemH 0
/ItalicAngle 0
/CapHeight 676
/FontName/ROZBKM+Times-Bold
/Type/FontDescriptor
/Descent -203
/Flags 262178
/FontBBox[-168 -218 998 934]
>>
endobj
35 0 obj
<<
/Name/F6
/FontDescriptor 34 0 R
/Type/Font
/BaseFont/ROZBKM+Times-Bold
/Widths[250 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 721 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 499 555 443 555 443 332 499 0 277 0 0 277 831 555 499 555 0 443 388 332 555]
/LastChar 117
/FirstChar 32
/Subtype/Type1
/Encoding 32 0 R
>>
endobj
36 0 obj
<<
/Differences[32/space 46/period 73/I 84/T 97/a/b 108/l]
/BaseEncoding/MacRomanEncoding
/Type/Encoding
>>
endobj
37 0 obj
<<
/Length1 707
/Length 707
/Subtype/Type1C
>>
stream
  FPUAPO+Frutiger-Bold   @¯ ¯¯¯¯˚:˚é˙|˙;
 ãã
 ãã      +√  ã ï•≠Copyright (c) 1988, 1990, 1994 Adobe Systems Incorporated.  All Rights Reserved.Frutiger is a trademark of Linotype-Hell AG and/or its subsidiaries.Frutiger 65 BoldFrutiger    5 B C M  *     $ ±%&:L¸-†v¯‡˜˜d˜ ˜d˜ ¯‡˜\˜¸∞˚˜\-Ì5·˜,€˜ÌØ˜˜c˜˚˜
|Î¯	≠∏ƒ°ƒ⁄∞o8ASIÜrXXrf^>ä)‰TÊ»Œ´ƒ™çBå{ãiêp\˜
à≥âØä≤ä±ä≤ãøÕ˜,JÃ˚1RE|sW¨”˚Á⁄‰ï«≈cÖfunovkyb[fû∑dÛ/Án®˜ﬂÛ˜sw–˜˜|˜ ñ˜`˜ó”≠Á·‚£,FDr+32nÈ‘D˚˚ó˜$ çûT≤…wƒ˜2≈˜˜!˜"Q˜˚2E\nZfâ˜¡˚†v˘Çw”˜”˜˘Ç˚†v˘Nw–˜ –˜ ˘N˚ ã˜ –˜ –˜ ˜ ˚ ó˘Nó˚Wó˜só˜®ëÒì¸˙óó˘Nó˚\ó˜xó˜®ëıì¸˛ó	Ì
˜ å˜™˘endstream
endobj
38 0 obj
<<
/XHeight 762
/Ascent 750
/FontFile3 37 0 R
/StemV 140
/StemH 0
/ItalicAngle 0
/CapHeight 698
/FontName/FPUAPO+Frutiger-Bold
/Type/FontDescriptor
/Descent -210
/Flags 262176
/FontBBox[-166 -250 1000 935]
>>
endobj
39 0 obj
<<
/Name/F17
/FontDescriptor 38 0 R
/Type/Font
/BaseFont/FPUAPO+Frutiger-Bold
/Widths[278 0 0 0 0 0 0 0 0 0 0 0 0 0 278 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 278 0 0 0 0 0 0 0 0 0 0 556 0 0 0 0 0 0 0 0 0 0 0 0 556 611 0 0 0 0 0 0 0 0 0 278]
/LastChar 108
/FirstChar 32
/Subtype/Type1
/Encoding 36 0 R
>>
endobj
40 0 obj
<<
/Differences[32/space 40/parenleft/parenright 44/comma/hyphen/period/slash/zero/one/two/three/four/five/six 56/eight/nine/colon 65/A/B/C/D/E/F 73/I 77/M/N 82/R/S/T 97/a/b/c/d/e/f/g/h/i/j 108/l/m/n/o/p 114/r/s/t/u/v 121/y/z 135/aacute 142/eacute 146/iacute 151/oacute]
/BaseEncoding/MacRomanEncoding
/Type/Encoding
>>
endobj
41 0 obj
<<
/Length1 4279
/Length 4279
/Subtype/Type1C
>>
stream
  ZTOKAW+Frutiger-Light   @¯ ¯¯¯¯˚,˚é˙|˙#
 ãã
 ãã      ç«  { ï¶ÆCopyright (c) 1988, 1990, 1994 Adobe Systems Incorporated.  All Rights Reserved.Frutiger is a trademark of Linotype-Hell AG and/or its subsidiaries.Frutiger 45 LightFrutiger  6  $ B T P  D M ” O J E F G U Q S V 4 H      ' 5  N  % » C . W  	  
 I œ [  Z K ÿ   3  " * / & #  8   M º]^§∑È*L¨¸@Ä„!e¡ANdåƒPqç‹F]õ'ÇΩÊ	W	å	“

?
Æ
‘
Î/k’*êÊVäù“˜[z¸ú«¯Ó«ƒ–¯Õ˘@ûg8íb˚l˚˚)˚h˚l˜˚%˜p∑Ÿí¢±á«csEÖ]ã˚L(˜˜D˜AÒ˜˜Iº Ñt∑˚*¡aµ˜k¡˜1¡≥–˜ï |¯…ÜÆã™¥˜u˜Vƒ˚^I{xdN©∫Ωó¿‡™_4q˚˚JÉ˚?¨]¢)˜% “¨»ßçÖ˜$Tà˚˚(Q[§Œ˜˜ñ˜ù˚ô¡¯>¡t¢¥ ˜J–ÿ≠óy∏ºÖºÿ∞˜ ˜;˚èãÍÃ∏üÃÆ∏Ç|¨(ë¬ÿú^Uëp79e&˚(˜âûã˚QVjOZ]òûe-¡¯>¡≥–˜Ê–≥˜ì˚‘˚˜9˜9‘˜˜˜B˜˚9˚9B˚˚–˜
∆Í˜˜∆,˚
˚
P,˚˚PÍ˜
˚b¡¯>¡¥–¯4¯äëy_ôN˚+&˚˚1˚"€˚˜8ª≥éö∂Ö∆e}fÇcã˚EÏ˜˜–‰˜≠¥Ä|≠¸@†v˘Çw⁄ ⁄ ˘ÇL¸@†v¯íw‘˜$¿˜@˚& Ç0¿¯–π˜˜$<˚&˝W»⁄ ¯íL-†v¯hµa¡⁄ ˜§ ∏⁄ ˜Æ‡Ø˜‚≠M+˚  ˜⁄˜[ﬂ˚!eR]vâPÊNèbãcd¸@†v¯íw˜0ﬂ⁄ ⁄ ¯íL0 ˜pL7 -¡aµ¯>¡˜xwº–˜¬ º¯w˘ÇL˚⁄â§ÇY‘'˚*O˚˚/˚+—˚˜ ‘øßÃ≠çD: ¨¸˜ìÓ™˜˜˜≤˚..d˚˚˚l˜Ó˚*¡˜W¡˜E¡¥–˜¨–¯9€xmHx]˚Q‚˜ ˜Ò´˜P˜˚$˚5˚˚0˚- ˚˜=∫ƒïù∑˚À˜ßﬂƒËËÈØ32˚—†v¯\¡˜Z¡Åï˜ Ë˜ ¯\˜¡˚∑»ÇË·ùûáÑòè¬hípéw˚á˚  f$UÚ˚—¡¯2¡˜ ˜ø¯í˚˜%Lu˚'UÔ˚æ.è>˜™™ìëöáøyÑ{ÜsãXz±π˜ﬁ˜-˚Qv˜Z¡¯>µa¡‘ ˜¬–‹‘˚f ˜ΩçI™ªj€˜ —˜˜+˜/O˜˚*˚ d>o{â(èËL\¯˚ì(l˚˚˚d˜ËË≤˜˜˜™˚(˚—†v¯\¡UÕ⁄ –⁄ ˜ê0Á¶˜ÔõúâáòÕéÄyé|J`VRtâPÌLèfãvS-¡aµ¯hw⁄ ˜§ ∏¯q¯íL˚Æ6g&˚4i…Î˜ L˚⁄˚ª7˜ı±ƒπ†çH0»á¥ã≥≤˚*«¯Ó«t¢≈–˜è–ÿ«ù{∞¿}œ˜ ˜√˜!˜`˚‘åã˜ Â⁄©”∫ºÇz™(ñ ÿù[Têi˚)E˚˚K˜‘zã˚(D_5J[ö•b-˚l¡p¶˜6¡¯2µa¡º–˜¬ Æ˜
˜ìÓ™˜˜˜Ø1˚.b˚ ˚ cÔ¯˜ìLÆQâ»\_îG˚*O˚˚/˚ø˚"˜7Ã√•’≠ç˚$}˚
˚6TSõüdDÜLÜÉ•»xŒ˜CÀ˜˜"ãﬂÌ‹Ì‹ﬂ:˚˜n¡˜"¡˚ ⁄˜n7-†v¯ùw˜Ÿãw˜¶–ÿ˜¯ ±^®˜Ó˝ –˘NM-†v˜5«¯,–¢ ˜¢–˜¯˜q˚¢˜†¯,ç˚·¸h˜·˚5–˜5Ú«$¯q3˚Œ¸i-Ñ«˜¯v˜ï«π–\–˜≠–]–(œ¯≤/ŒV”ií0jE_ ˚˜Q˜˜˜º˜˜D≥,≠$ÕØÿƒ·˜'º˚(6˚]˚	í¯	˚˘+:g9;8ªŸÏ›ß‹¨ÀjÓl3l˚ƒ˜Û‘œØ‘Ã÷hAC>^LlRß7≥€˚b†v˜›«˜ç«ÿ–ÿ–˜›˜è«˚è˜ç˜õ«˚‡˚*†v˘«˜l–˜l–˘˜b«¸uO˜b-Ñ«¯‰«º–˜‘–˜™˘˜%ö˚H˚˚|˚H˚%˚%|˜H˜˜ö˜H˜%«˚N`˚U˚7˚&©˚f˜[˜[©˜f˜&˜7`˜U˚N˜K†v¯hµa¡⁄ ˜â ˜â º˘ä˜ÛÓQ”$;O[Otâ‰{Aû^˚mKhwâå‹·Nèbãcd¸ ˜Æº˜œ∆–‹¶RC˚Á ˜Æ˜œ∆–‹¶RC˚Áîv˘fwl˜Ël–˜£˘fFúã«¯÷«€–¯–˜)˘˜0˜D˚i˚j˚;˚ZRFO˜˜{˜=Ï˜ë˜`(˜$˚é˚A˚*¡aµ˜k¡˜1¡¥˜$≥–ﬁ˜@ç ˜Ç
¿¯–π˜˜$<˚±˝Wu¯…ÜÆã™¥˜u˜Vƒ˚^I{xdN©∫Ωó¿‡™_4q˚˚JÉ˚?•]¢)˜% “¨»ßçÖ˜$Tà˚˚(Q[§Œ˜˜ñ˜ù-¡aµ¯>¡˜xw‘ ˜¬–H‘ º‹çJ≠øo‘˜ —˜˜+˜/O˜˚*'YBrÇâ˜⁄L¯¸É(l˚˚˚d˜ËËØ˜˜˜™˚(˜É†vãﬂ¯µ–·–¯◊–∏·–˘	ç˜ö˝	∆˜í˘	ç˝	–˘N(p˚î¸˙˚ì¯˙ ˚bã–¯Mwî¯>¯G¯íI˚(¸Mâ˚!¯MF˜A¸í’-Ñ«_∑˜`«˜‹«º–˜Œ–º˜©˘U˚#6-˚˚A˜^ÁÃ ¶∆Øç˚"S˚+˚Iéc]îònHÖIåÇ∞∞Ñ±˜Ä⁄˜>˜gº˜8d˜;˚MÄ¸*X»ÒÈ¬“ÒÚ∫45/PL'†v˘àwµ ˜ì˚ B˜ >˜&˜6˜6ÿ˜&‘˜ a4˚7˚#˚<˚<ﬂ˚#‚˚-ã«¯›«Ω‡˜á÷Ω¯7«˚‚˜˜ÂÓÒ˜ãÛ˜2ƒ˚RGurXóL¬´Ωù ã–¡WA67#7.˚4˚E†v˘àw˜A ¢˘à‘˚ ÿ˚&˚6˚6>˚&B˚ µ‚˜ﬂ˜#˜<˜<7˜#4˜-†v¯h¡˜xw⁄ ˜§ ⁄ ˜•‰≤ı˜Ûú?3˚ƒ ˜≈˜fÊ˚@RaSpâ˜⁄L˚*¡˜W¡˜E¡¥˜$¥–›˜@•–˜Ç¿¯–π˜˜$<˚±˝WÍ¯9€xmHx]˚Q‚˜ ˜Ò´˜P˜˚$˚5˚˚0˚- ˚˜=∫ƒïù∑˚À˜ßﬂƒËËÈØ32˚bã¡¯&¡´¯´¯¡˚«˜«¯&¡¸U˜ª˚«¸'˚—†v˜–¥˜è¥˜˜è–˚è˚b˚l¡˘4wî¯>Ÿ¯íF˜I¸ò~^wIy^UãtèèÖU†Ü£à¢ã“Ø——£˜`¯ﬁI˚'¸=ä¸@˚l¡˘4w˜0ﬂ⁄ o˚gâïùà¶Á¢…›¯⁄L¸“VÜ^KzééÇ0˜>˙
L7 -¡¯>¡¥˜$≥–˜˜@¬–˜;Ç(¿¯–π˜˜$<˚Õ˝W‘≥˜ì˚‘˚˜9˜9‘˜˜˜B˜˚9˚9B˚˚–˜
∆Í˜˜∆,˚
˚
P,˚˚PÍ˜
-Ñ«˜–«˜e«Ì–˜ë–¯^˘N˚˘Ñ˚Ûæö¥í∆ã˜
ƒY˚ ˚-Z0ZSó£_Dy∫øÑΩ˜)ÙŸ˜.˜7◊˚UnÑÉtê˜t˜µ-Ñ«˜´«˜ë«¯)–˜*˜‡À÷˜˚!,b7YNí¶RÉI√v√Ñ«ã˜ ˜’˜ËW”.èç‡†«»‡˜ º˚QO~xXëJº¢øô¬ã÷‡h=˚˚"Å,y-†v˜›«˜ç«„–˜ã–˜1˘“Í‹Ñ˚*.l:BF¸–˜›ƒÕ©à1≥˚Ä◊˚˜¢u∫©Síç·ñ–«Â˜:¿˚˚H-Ñ«˜‹«˜`«{õ¬–˜Œ–Ï˜´Ñ˜#‡È˜˜A˚∏/JLpPgâ˜"√˜+˜Ià≥πÇ~®ëÕ,îffíe˚Ä<˚>˚gÏ˚8≤˚;˜Mñ¯ÏæN%-TD%$\‚·Á∆ Ôú†v˜O«¯Õò˘òŒ÷˜O˜Ù÷˚O”˚©˘N=˜M¸W˚√˜,¯¸@†v˘Nwÿ–ÿ–˘NFú†vãﬂ¯öÎãwÿ–¯–úÿ–¨¯Óç˜Ò¸ÓË˘NF\¸˙â˚˜¯˙4˚*ã«˜°«˜ç«·–·˜ˆ«˚±˜°˜ó«˚ó˜ç˜•«˚Í-ã«˜•«˜â«€–˜ç–[–Ù€˜˜%˜∫˜,ÁO≈3õçx·ú¥¿‰˜ ±˚˚:–¸»ÙÒˆ~˚˚"r.Cç¯÷Íx∆Ë}&˚*xB>ãﬂ˜ÍﬂÌ‹`˜G¯í:7‹†:¸>‹ﬂ:ó˘Nó˚\ó˜xó˜©íÛì¸¯ëó˘Nó˚\ó˜xó˜®ëıì¸˛ó	¡
 
yXO	˜™˘endstream
endobj
42 0 obj
<<
/XHeight 762
/Ascent 750
/FontFile3 41 0 R
/StemV 63
/StemH 0
/ItalicAngle 0
/CapHeight 698
/FontName/ZTOKAW+Frutiger-Light
/Type/FontDescriptor
/Descent -210
/Flags 32
/FontBBox[-152 -250 1000 911]
>>
endobj
43 0 obj
<<
/Name/F18
/FontDescriptor 42 0 R
/Type/Font
/BaseFont/ZTOKAW+Frutiger-Light
/Widths[278 0 0 0 0 0 0 0 278 278 0 0 278 333 278 278 556 556 556 556 556 556 556 0 556 556 278 0 0 0 0 0 0 667 556 667 667 500 444 0 0 222 0 0 0 889 667 0 0 0 556 500 500 0 0 0 0 0 0 0 0 0 0 0 0 500 556 444 556 500 333 556 556 222 222 0 222 833 556 556 556 0 333 389 333 556 444 0 0 444 444 0 0 0 0 0 0 0 0 0 0 0 0 500 0 0 0 0 0 0 500 0 0 0 222 0 0 0 0 556]
/LastChar 151
/FirstChar 32
/Subtype/Type1
/Encoding 40 0 R
>>
endobj
44 0 obj
<<
/Differences[32/space 40/parenleft/parenright 47/slash 68/D/E/F 77/M/N 80/P 82/R/S/T 97/a 99/c/d/e/f/g 105/i 108/l/m/n/o/p 114/r/s/t/u/v 120/x 146/iacute 151/oacute]
/BaseEncoding/MacRomanEncoding
/Type/Encoding
>>
endobj
45 0 obj
<<
/Length1 2915
/Length 2915
/Subtype/Type1C
>>
stream
  ZYCDAX+Frutiger-LightItalic   C¯ ¯¯¯¯˚#˚é˙õ˙)
 ãã
 ãã  .  *  q«  ' ï≠µCopyright (c) 1988, 1990, 1994 Adobe Systems Incorporated.  All Rights Reserved.Frutiger is a trademark of Linotype-Hell AG and/or its subsidiaries.Frutiger 46 Light ItalicFrutiger     3 F G S O D J B 1 U T & E 4 Y P  	 .  ' 
 % H ÿ / W M 5 N Q V ” "   Z ∂Yµ˘&≥ÙFï ;î…Kêß’L’=z°π‚iŸ	7	n¸-†v˜›«˜ç«¯j–∞——˜›‹√£|Tõ»˚óœI˜†Å±Ñ∞Qïç˜ê‚œ˜˜:≤˚à˚2¡O“¬q<˚˚k.B˚*¡˜W¡˜E¡≤ ˜“ ¯p˜Åé´è´™˜O’˚˚8'˚/˚?˚ÊD˜ﬁ≤õñ©ê»cz]zLã1J√Ìôåôçòñ¡Ëú”ﬂÌ›ÆT8â~ä}˚—†v¯\¡˜Z¡Äñ»¯Ë‘ÕÌ¯\˜ò¡˚ì±ú‹ù⁄÷ã©õÉâêö¿`îttçs˚l˚3xÄX˚~U˜˚—†v¯\¡UÕß˜Û˚è –ßŒø˜è(Áû¥˜ÚùûäÑúöŒzézèvãI_dYkâHêùé¶é´LàkÜmÖn-†v¯hµa¡˜ ˜à–∏ßÕΩ˜Ü£˜	∆˜˜ãÀ≠eOiáuÑjQ˚≠Õƒ˜°í´ì±ãÆÎGø/LKhUhâPêùé¶é´LâráuÖi˚b¡¯>¡≤–¯g¯äïqNïa˚Y%˚˚H˚“˚˜'ø≥íì£ì kÄe~eã,E⁄Ù˜Ÿı˜%≥∆~Åû¸@†v¯íw˜0ﬂß˜u.ËßÕ˜ ¯íI(˜	˜p@y7÷˚*¡aµ˜k¡˜1¡ö–˜á Å–∫¯H˜óî≥è∞üıQ«˚OQx|gÑK≠ú≈¶∆ã—≤cEvä|â|çwtçq˚˚<l˚)7ŒP⁄Ñ÷√¢À∂çDÜuâqàp çÆí∫ï≤®˚Ÿñ˜˜ò‡†üâã† }U!˚
X[´≈˚*†v˜¬«˜®«¯l–˜à˘‘‹’x+˚$a!=˚(˚˛–Õ˜¬Ì˜˜“˜*˜'"ß˚˚˚—¡¯2¡Ê–˜C¯í'}UÒZ˚vÜuy:ã_T≥c“•ûêîûë¡yÅzáxãfv°≥¨ì¨í≠¡˜ê˜ò¡˚™˜Cr˚ô¡¯>¡–Õ˜–}õwºπÉ¿Óı∑˜˜˚`ñã‚“—õΩ±µÄx¨†∆aú`ì]ã9 b&˚˜]êã˚<8tN`aö°g˚*ã«˜°«˜ç«∞¯|∞˜˙ï«˚≥√˜°˜öñ«˚ôæ˜ç˜©ñ«˚Ï-¡aµ¯>¡˜xw≤–˜úÃòv∫¯‡˘ÇIE˚‚â—xLØA˚6.˚B˚"˚Ω$˜Ñ·æ±¬∞çDÑwÖjàoÃç£ëÆî¥™˚ÓÈ˜
«˜0˜„µD0˚9˚+˚3fŒ‡˚*«¯Ó«˜–˜P–¯õ˘;†ZUïP˚˚P˚˚5˜ïã˚%˚ 'b-YQõßbvI™z¡vÊã˜˜◊˜"˜H˚ïòã˜ÈÂØÿººu∂˚b†v¯íwb¯õbÿ˜N˜lË˚l”˚˜°˜h˜Ö;˚6˚R2˜RF˜˚Ö-¡¯>¡≤–˜Ò–≤˜f˚Ÿ,˜˜Dˆ˜%˜>˜B‚˚˚A˚˚!˚?–Å˜Õ˜˜!Ó∂E+˚A˚ ˚2U—„†v˘àwœ ˜ﬁ˘à˚˚4˚˚4˚l˚≤˚∫˚∏a˜ q˜˜˜p˜˜A˜˜7˜É†vãﬂ¯Ø÷∞˘˜∞∞À˜˘ç˜˝ƒ¯"˘ç˚˝œ˜(˘N p¸¸˙˚¯˙+îv˘fwÖ˜ËÖŒ˜•˘fF˚b†v˜›«˜ç«ß¯vß–“˜›˜ìó«˚îæ˜ç˜üò«˚‚†v˘àw˜O ˚ ˜˜4˜˜4˜l˜d˜\˜^µ˚ •˚˚˚p˚˚A˚˚7úã«¯÷«¯◊–˜á˘‚˜)ÔK˚0˚v˚˚˚f˚9O˜g˜ì˜%˜=˜ç˜h˚,œ˚O˚-˚l¡˜6¡¯2µa¡≠–˜‹ß‹Ñ˚Jp»¿Ñ∆˜c∞È˜E±◊˜Û$ï∑î≤ê†LÅhÉhÖiâ‹ﬁ{F¨;˚>1˚-˚5˚»)˜œ≈£Ω∏çÉfm˚dC˚&ãTXñ¨YË˜⁄˜Õ˜(˜Ë∏D0˚	J˚˚-a–‡-¡¯>¡√˜$≤–˜F˜8í–˜;(˜¯÷∫˜	˜$<¸˝f‘≤˜f˚Ÿ,˜˜Dˆ˜%˜>˜B‚˚˚A˚˚!˚?–Å˜Õ˜˜!Ó∂E+˚A˚ ˚2U—„ú†vãﬂ¯¶ﬂãwß˘)òßÀ†˜¯˙ç˜}¸˙›˜(˘NLP˚¸˙â˚}¯˙9˚bã–¯MwÃ¯A¯Ç¯íD˚¸MâR¯MKœ¸í◊¸@†v˘Çwß˜vßÕ˜4˘ÇI˚*†v˘«„¯é„˘˜h˚˝”˜˘˜hó«¸Å˜K†v¯hµa¡˜ ˜m«˜é–ºßÕ¿˜óûÁ¿˜	Ûã»£`SeÖmÑlR˚¢Õ¿˜óûÁ¿˜	Ûã»£`SeÖmÑlR˚¢Õ≈˜®ì∞í≤ãüËSƒ3:P`Djâ’àV≥CEcrK[âPèùè¶é´LâpÜiÖr-˚Qv˜Z¡¯>µa¡˜ ˜ú–‹y˚fÕ…˜…çE†∆b”˜@‚˜>˜2˜PÁ˚FKiUiâhèûê•ç™LáeÉ`Ée\®˚O˜ ‘˜0˜„ØG7˚
P˚0˚h2d›€-¡aµ¯hwƒ–˜à ∏¯©¯íIY˚Üs˚	P˚˚ãKi±«≠è°í¨≈˜≠IR˚°ÑkÉeãh+œWÁ ÀÆ¡ÆçHÜyàpàk ç§è°ë≠¸@†v¯íw„˜$ß˜B8˜8ã(˜¯÷∫˜	˜$<˚`˝f–ßÕ˜ ¯íIó˘Nó˚\ó˜xó˜©íÛì¸¯ëó˘Nó˚\ó˜xó˜®ëıì¸˛ó	¡
–
yXO	˜™˘endstream
endobj
46 0 obj
<<
/XHeight 762
/Ascent 750
/FontFile3 45 0 R
/StemV 69
/StemH 0
/ItalicAngle -12
/CapHeight 698
/FontName/ZYCDAX+Frutiger-LightItalic
/Type/FontDescriptor
/Descent -210
/Flags 96
/FontBBox[-143 -250 1031 917]
>>
endobj
47 0 obj
<<
/Name/F19
/FontDescriptor 46 0 R
/Type/Font
/BaseFont/ZYCDAX+Frutiger-LightItalic
/Widths[278 0 0 0 0 0 0 0 278 278 0 0 0 0 0 278 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 667 500 444 0 0 0 0 0 0 889 667 0 500 0 556 500 500 0 0 0 0 0 0 0 0 0 0 0 0 500 0 444 556 500 333 556 0 222 0 0 222 833 556 556 556 0 333 389 333 556 444 0 444 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 222 0 0 0 0 556]
/LastChar 151
/FirstChar 32
/Subtype/Type1
/Encoding 44 0 R
>>
endobj
48 0 obj
<<
/Count 4
/Type/Pages
/Kids[49 0 R 50 0 R 51 0 R 52 0 R]
>>
endobj
49 0 obj
<<
/Contents 1 0 R
/MediaBox[0 0 595.276 793.70099]
/Resources<</Font<<
/F5 31 0 R
/F0 11 0 R
/F4 27 0 R
/F2 19 0 R
/F3 23 0 R
/F6 35 0 R
/F1 15 0 R
>>
/ProcSet[/PDF/Text]/ExtGState<</GS2 3 0 R/GS0 2 0 R>>>>
/Type/Page
/Parent 48 0 R
>>
endobj
50 0 obj
<<
/Contents 4 0 R
/MediaBox[0 0 595.276 793.70099]
/Resources<</Font<</F0 11 0 R/F2 19 0 R>>/ProcSet[/PDF/Text]/ExtGState<</GS2 3 0 R/GS0 2 0 R>>>>
/Type/Page
/Parent 48 0 R
>>
endobj
51 0 obj
<<
/Contents 5 0 R
/MediaBox[0 0 595.276 793.70099]
/Resources<</Font<</F0 11 0 R/F18 43 0 R/F17 39 0 R/F19 47 0 R>>/ProcSet[/PDF/Text]/ExtGState<</GS2 3 0 R/GS0 2 0 R>>>>
/Type/Page
/Parent 48 0 R
>>
endobj
52 0 obj
<<
/Contents 6 0 R
/MediaBox[0 0 595.276 793.70099]
/Resources<</Font<</F0 11 0 R/F2 19 0 R>>/ProcSet[/PDF/Text]/ExtGState<</GS2 3 0 R/GS0 2 0 R>>>>
/Type/Page
/Parent 48 0 R
>>
endobj
53 0 obj
<<
/PageLabels 7 0 R
/Pages 48 0 R
/Type/Catalog
>>
endobj
54 0 obj
<<
/CreationDate(20050104074500)
/XPressPrivate(%%DocumentProcessColors: Black\n%%EndComments)
/Producer(QuarkXPress(tm) 6.1)
/Creator(QuarkXPress(tm) 6.1)
>>
endobj
xref
0 55
0000000000 65535 f 
0000000015 00000 n 
0000010561 00000 n 
0000010625 00000 n 
0000010688 00000 n 
0000021171 00000 n 
0000031300 00000 n 
0000036380 00000 n 
0000036418 00000 n 
0000036890 00000 n 
0000046338 00000 n 
0000046555 00000 n 
0000047299 00000 n 
0000047465 00000 n 
0000050524 00000 n 
0000050756 00000 n 
0000051149 00000 n 
0000051379 00000 n 
0000057085 00000 n 
0000057310 00000 n 
0000057965 00000 n 
0000058385 00000 n 
0000068428 00000 n 
0000068648 00000 n 
0000069352 00000 n 
0000069477 00000 n 
0000070658 00000 n 
0000070885 00000 n 
0000071211 00000 n 
0000071455 00000 n 
0000076268 00000 n 
0000076489 00000 n 
0000076971 00000 n 
0000077116 00000 n 
0000079426 00000 n 
0000079646 00000 n 
0000080018 00000 n 
0000080142 00000 n 
0000080929 00000 n 
0000081154 00000 n 
0000081488 00000 n 
0000081824 00000 n 
0000086185 00000 n 
0000086406 00000 n 
0000086923 00000 n 
0000087157 00000 n 
0000090154 00000 n 
0000090383 00000 n 
0000090862 00000 n 
0000090940 00000 n 
0000091193 00000 n 
0000091387 00000 n 
0000091604 00000 n 
0000091798 00000 n 
0000091866 00000 n 
trailer
<<
/Size 55
/Root 53 0 R
/Info 54 0 R
/ID[<B7BC69F55575A8B6424F46812E5EAD43><B7BC69F55575A8B6424F46812E5EAD43>]
>>
startxref
92041
%%EOF
